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In recent years, the use of biologically- and peptide-based therapeutics as a template for new 
lead compounds has increased rapidly. A common characteristic of the peptides used in drug 
development, is the high frequency of disulfide bridges. It is crucial for the biological effect 
of the peptide that the formation of these bridges is correct. Presently, there is no generic 
method for deciding the sulfide connectivity in a disulfide-rich peptide. As toxins are neuro-
pharmacologically active, it is an interesting group to examine. Conotoxins are diverse and 
well-studied, and is therefore suited as a model to develop a general method for analyzing 
disulfide-rich peptides.  To investigate the folding of both commercially available and self-
synthesized Conotoxins, an UHPLC-MS/MS method was developed where one disulfide-
bridge was reduced at the time and alkylated with different maleimides. The results from the 
UHPLC-MS/MS method were examined in a peptide- and protein-structure determination 
software.  
TCEP was used to reduce the disulfide-bridges. Available literature about reduction of 
peptides and proteins does not discuss breaking of single disulfide-bridges, but of how to 
effectively fully reduce all bridges. A small activity study of TCEP was conducted to assess 
effective concentrations and if the effect was influenced by pH. 
The Cysteine-connectivity of Conotoxin α ImI was confirmed by use of an in-vial reduction 
and alkylation method. The method developed was also used to establish the Cysteine-
connectivity in two synthesized and oxidized disulfide-rich peptides. The method was further 
developed to include peptide reduction on a solid phase extraction column.        
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Traditionally, most drug discovery programs concentrate on small-molecule natural products 
as a template for a new lead compound. In recent years, biologically- and peptide-based 
therapeutics has gained on the small-molecule drugs. Currently the success rate for launching 
biologics and peptide-based drugs is doubled compared to traditional small-molecule drugs 
(1). Peptide-based drugs vary in size from monoclonal antibodies with four peptide-chains 
creating a quaternary structure (2), to small disulfide-rich peptides with a single peptide-chain 
of less than 100 amino acids and derivatives thereof (1).  
 
1.1 Disulfide-Rich Peptides 
 
Cysteine (Cys) occurs in about 2.3 % of mammalian proteins. In small disulfide-rich peptides 
however, Cysteine residues accounts for more than 10 % of the sequence. These Cysteine 
residues are able to form reversible, covalent intra- and intermolecular disulfide-bridges. The 
bridges form post translational between the side-chain sulfhydryl groups. It is one of the most 
common post-translational alterations to occur. The oxidation of the two sulfhydryl side-
groups into a disulfide-bridge stabilizes the three-dimensional structure of the folded peptide-
chain. This stabilization is of high importance for the biological function of the peptide. The 
peptide-chain in small disulfide-rich peptides (DRPs) normally folds into a limited number of 
secondary structure elements that are stabilized by two or more disulfide-bridges. It is crucial 
for the biological effect of the peptide that the forming of these bridges is correct. The natural 
oxidation process is complex, with bonds forming between two Cys-residues just to break 
again so a different bond may be formed involving a different Cys-residue. The final, stable 
product of this process is called the peptides native fold.  
The number of possible isomers formed through natural oxidation increases with increasing 
numbers of Cys-residues in the peptide. The mathematical formula is given in Equation 1. 
The equation shows that a peptide with four Cys-residues will have three possible isomers, six 






Equation 1: Possible isomers formed in a random oxidation processes increases with increasing numbers of Cys-
residues according to this formula, where N is the number of isomers formed through random oxidation of n thiol-
groups to form j sulfide-bridges.  
 
 
The venom-derived peptides conotoxins from marine cone snail venom, ST enterotoxins and 
other small disulfide-rich peptides such as plant-derived cyclotides, knottins and highly 
knotted antimicrobial defensins peptides are highly constrained peptides with a wide range of 
therapeutic applications. Interestingly, some of these peptides are potential peptide-based 
templates for drug design in addition to their wide range of pharmaceutical activities (1). As 
toxins are neuro-pharmacologically active, it is an interesting group to examine. Conotoxins 
are diverse and well-studied (3), and is therefore suited as a model to develop a general 




While poisons are absorbed by oral intake or through the skin, venoms are actively injected 
by the venomous animal. The peptide and protein components of venoms are called toxins. 
Toxins from all four main groups of arthropods target voltage-gated ion channels (4). 
Conotoxins are toxins from the cone snails. Due to the vast variety of prey, each species of the 
conus family has developed a large array of toxins.  There are conotoxins that interact with 






 channels of its prey (3), others interact with a 
diversity of membrane receptors and  other transporters (5). So far five different groups of 
conotoxins are characterized. They are named α-, δ-, κ-, µ- and ω-conotoxins and they each 
interact with a different target (6).  
Conotoxin alpha ImI (Cα) from conus imperialis was one of the first conotoxins to be 
characterized. It is part of the α-family of the conotoxins which interact antagonistic with 
nicotinic-acetylcholine-receptors (3). The amino acid sequence of Cα is Gly-Cys-Cys-Ser-
Asp-Pro-Arg-Cys-Ala-Trp-Arg-Cys-NH2, with two disulfide-bridges; one between Cys-
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residue 2 and 8, the other between Cys-residue 3 and 12 (7). Figure 1 is graphic display of the 
bioactive, native isomer of the peptide. 
 
 
Figure 1: Conotoxin α ImI. Loops colored purple, helix turquoise and Cys-residues yellow. Disulfide-bridges are 
stabilizing the fold of the peptide, giving it its active isomer. 
 
 Conotoxin omega GVIA (Cω) comes from the species conus geographus, targets Ca
2+
 
channels, has three disulfide-bridges and the sequence Cys-Lys-Ser-Hyp-Gly-Ser-Ser-Cys-
Ser-Hyp-Thr-Ser-Tyr-Asn-Cys-Cys-Arg-Ser-Cys-Asn-Hyp-Tyr-Thr-Lys-Arg-Cys-Tyr-NH2 
(3). The three bridges are formed between residue 1 and 16, residue 8 and 19 and between 15 
and 26 (8). Figure 2 shows a graphic display of the bioactive, native isomer. Note that 
Conotoxin ω GVIA is a β-sheet structure while Conotoxin α ImI has an α-helix as secondary 





Figure 2: Conotoxin ω GVIA, β-sheets colored red, loops purple and Cys-residues yellow. The disulfide-bridges are 





2. Theoretical Background  
2.1 Peptide Synthesis 
 
Solid phase peptide synthesis involves, as the name implies, a solid support for the peptide to 
be assembled on to. The C-terminal of the first amino acid in the peptide-chain is attached to 
an insoluble support via its carboxyl-group. If the side-chain of the amino acid has a 
functional group i.e. aspartic acid, it needs to be masked by a protecting group that is not 
affected by the reaction conditions employed during the assembly of the peptide-chain. This is 
referred to as orthogonal protection, and is necessary to avoid agglomeration, formation of 
dimers and even branching of the peptide-chain. The N-terminal of the amino acid is also 
protected, but is removed when the coupling stage is finished. This allows the next amino acid 
in the sequence to attach and make a peptide bond between the first and the second amino 
acid. A coupling reagent is added to facilitate the reaction. After the coupling, the peptidyl is 
washed of excess reagents and the N-terminal is deprotected before the process is repeated 
until the desired peptide-chain has been assembled. The fully assembled peptide is then 
chemically cleaved from the resin. Protection-groups on the side-chains are removed during 
the cleavage step. The protection-groups that are removed from the side-chains are still 
reactive. It may re-form the attachment to the side-group, or form a new attachment on a 
different residue. To prevent this, the cleaving mixture has to contain scavengers that react 
with the de-attached protector and render it unreactive (9). 
 
9-fluorenylmethoxycarbonyl (Fmoc) - protection of the N-terminus is currently favored over  
t-butyloxycarbonyl (Boc) - protection, since Fmoc uses milder conditions. 
Boc is still frequently used as a protector of active side-chains in Fmoc-SPPS. t-butyl ester 
(OtBu), 2, 2, 4, 6, 7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf), t-butyl ether (tBu) and 
triphenylmethyl (Trt) are other recommended side-chain protectors in Fmoc-SPPS. Table 1 





Table 1: Name and molecular structure of Fmoc and the side-chain protecting groups recommended in Fmoc-SPSS, 
and their removing agent 






















   
There are recommendations on which protecting groups that are suitable for which amino 
acid. The different protectors have different chemical properties and will need different 




Table 2: The amino acids, the functionality of the side-chains, and their recommended protecting groups; NA = not 






Alanine NA NA 
Arginine guanidino N Pbf 
Asparagine Amide Trt 
Aspartic acid Carboxylic acid tBu 
Cysteine Sulfhydryl Trt 
Glutamic acid Carboxylic acid Trt 
Glutamine Amide tBu 
Glycine NA NA 
Histidine Imidazole Trt 
Isoleucine NA NA 
Leucine NA NA 
Lysine Amino Boc 
Methionine NA NA 
Phenylalanine NA NA 
Proline NA NA 
Serine Hydroxyl tBu 
Threonine Hydroxyl tBu 
Tryptophan Indole Boc 
Tyrosine Phenol tBu 
Valine NA NA 
 
Chemical oxidation is a method used to ensure the correct oxidation of the sulfhydryl side-
chains of the Cysteine residues into the native isomer of the peptide. This is done by 
protecting Cys-residues with protectors with different qualities. The protectors, 
triphenylmethyl (Trt) and acetamidomethyl (Acm) cleave off the side-chain of Cys at 
different chemical environments. Trt is removed by TFA in the cleaving-step, while Acm is 
stable in acidic environment. Acm will therefore still be attached to the Cysteine sulfhydryl-
group even after cleaving, and needs to be removed by iodine in a separate step. The 
molecular structure of Acm is presented in Figure 3. By protecting the two Cys-residues of 
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one of the native disulfide-bridges with the same protecting-group they are deprotected at the 
same time and therefore oxidize to form a disulfide-bridge. The second native bridge is then 





Figure 3: Molecular structure of Acm 
 
 
2.2 Activity Studies of TCEP 
 
5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB) is previously used to study the activity of 
reducing agents such as tris(2-carboxyethyl)phosphine (TCEP) (10). DTNB is also known as 
Ellman’s reagents with the molecular structure presented in Figure 4.  One molecule of DTNB 
is reduced to two molecules of 2-nitro-5-thiobenzoate (NTB).  
 
 
Figure 4: DTNB is color-free and has no absorption at 412 nm unlike the reduced structure with its distinct yellow 




The proposed mechanism of reaction between DTNB and TCEP is shown in Figure 5 and 
occurs by breaking the bond between the two sulfur-atoms which can be compared to a 




 at 412 nm 
(10). By measuring the absorbance of reduced DTNB after different reaction times and at 
different pH, this fact can be utilized in activity studies of reduction agents used in proteomics 
to reduce disulfide-bridges. The stronger the absorbance, the more DTNB has been reduced, 

















































Figure 5: Reaction between DTNB and TCEP. The product of the reaction oxidized TCEP and 2 molecules NTB. The 




2.3 Reduction and Alkylation of Disulfide-Bridges 
 
The oxidation of cysteine residues to form disulfide-bridges is one of the most common post-
translational alterations to occur. The natural process of oxidative folding is very complex (1). 
To reverse the oxidation is not as complicated, but it does not happen spontaneously after the 
native fold has been made. Thus a reduction agent is needed. Dithiothretiol (DTT) and TCEP 
are two reagents used in proteomics to reduce disulfide-bridges. The latter is deemed more 
effective and suitable for disulfide-bonds in proteins. TCEP is claimed to be efficient at acidic 
pH where DTT is not, and does not react with the peptide-chain’s active side-groups where 
DTT does (11). 
  
Figure 6: Structural formula of TCEP  
TCEP is colorless, odorless and readily soluble in water (10). An aqueous solution will have a 
pH of 2.5, and a buffer is needed to adjust the pH of the TCEP solution to the desired value.   
  
Figure 7: Structural formula of DTT 
DTT is soluble in water and a variety of organic solvents. It is colorless as an aqueous 
solution, but do have an odor due to the sulfhydryl-groups. 
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The proposed mechanism of reaction involves the phosphine group that forms a radical 
intermediate involving two electrons followed by the de-protonation of the sulfhydryl group 
that produces the final oxidation product after direct nucleophilic attack by water (TCEP), or a 
nucleic attack from the deprotonated sulfhydryl group with the lowest pKa (DTT). In both 
cases, the oxidation is irreversible and occur in one single step (11). Due to its reaction 
mechanism involving deprotonation of a sulfhydryl group, the DTT loses its reducing 
qualities at pH lower than 5, and optimal pH range is between 6.5 and 9 (10).  
After the reduction of the disulfide bond, an alkylating agent is used to ensure that the 
sulfhydryl-group of the Cysteine residues is inactivated. There are several alkylating agents 
commercially available, amongst these are maleimides.   
Maleimides is a group of alkylating reagents with a preserved ring-structure. The difference is 
the composition of the side-chain of the nitrogen-atom in the ring-structure. In its simplest 
form the side-chain is a mere proton. In methyl-maleimide (NMM) the side-chain is indeed a 
methyl-group as the name suggests, see Figure 8.  
 
 
Figure 8: 5-Hydroxy-2H-pyrrol-2-one (maleimide). The reaction happens between the sulfhydryl-group of the peptide 
and the electrons of the double-bond to form a thioether. 
Maleimides block the sulfhydryl-groups of the Cys side-chain by forming a stable thiolether. 
The reaction is irreversible and occurs in a single step.  See Figure 9 for proposed reaction 














Figure 9: The reaction between NMM and Cysteine’s sulfhydryl-group to form a thiolether. 
Most maleimides are poorly soluble in water due to its ring-structure and hydrophobic side-
chain. The electronegative oxygen-atoms bound to the ring by double bonds give the 
molecule polarity. When the side-chain is a proton, the molecule is polar enough to dissolve 
in water (12). Methylmaleimide is also readily soluble in aqueous solutions. An increase in 
side-chain size and hydrophobicity gives decreasing water-solubility of the maleimide. 
The alkylation reaction between the maleimide and the sulfhydryl-group is instantaneous and 
complete at pH 8. At a lower pH, the reaction is still complete given enough time; it is no 
longer instantaneous. At higher pH, the base-catalyzed ring opening of the maleimides 
incapacitates their activity (13). 
Figure 10 shows a simplified schematic reaction for the reduction and following alkylation of 
a DRP with two disulfide-bridges. Only the peptide backbone is drawn, with the disulfide 
bridges oxidized, reduced and alkylated respectively. The alkylating agents are of different 
size, weight and hydrophobicity. This can be used to differentiate between the Cysteine-
residues using the analytical tools of liquid chromatography and mass spectrometry coupled 



















































+ Alkylating agent 2
Alk1
  
Figure 10: Simplified sketch of the selective reaction between a peptide with two disulfide bridges, TCEP and two 




2.4 Solid Phase Extraction  
 
Solid phase extraction (SPE) is a sample preparation method mainly used on aqueous 
solutions, but is also used on organic solutions. There are several types of SPE-columns 
available; reversed phase, normal phase, ion exchange and even mixed columns. Within each 
category there are also several choices. This makes SPE a versatile preparation method that 
easily can be optimized to fit a wide range of analytes. One of the before mentioned extraction 
columns packed with stationary phases of choice is loaded with a sample. Contaminants are 
washed of the column, and the analyte is there after eluted. See Figure 11 for illustration.  
 
Figure 11: Schematic illustration of a SPE experiment. Used with permission by Terje Vasskog (14). 
A vacuum manifold is used to drag the washing solutions with its contaminants and the eluent 
with the analyte through the column. The technique is based on the difference in affinity to 
the solid phase between the wanted analyte and the contaminating components of the sample. 
To extract relatively non-polar analytes from aqueous solutions it is a good choice to use a 
hydrophobic stationary phase. The stationary phase can be based on silica particles with 
varying length of hydrophobic group from an ethyl group, trough aromatic and cyclic 
compounds to an octadecyl group. The octadecyl-silica columns are referred to as C18 
columns. Retention of an analyte will increase with the strength of its interaction with the 
adsorbent surface of the solid phase, and a C18 column will therefore give strong retention to a 
non-polar compound. Composition and pH of the washing solution must ensure the retention 
of the analyte through the washing step of the extraction while more polar contaminations are 
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washed away. The eluent must be strong enough to elute the analyte, but preferably not strong 
enough to elute hydrophobic contaminations (15). 
 
2.5 UHPLC-MS/MS 
2.5.1 Ultra High Performance Liquid Chromatography 
 
High performance liquid chromatography (HPLC) is a separation technique often used in the 
analysis of a wide range of compounds, hereunder peptides. The technique is based on the 
difference in affinity to the mobile- and solid phase between the compounds one wants to 
separate. Retention of an analyte will increase with the strength of its interaction with the 
adsorbent surface of the solid phase. Composition and pH of mobile phase both affect the 
retention of the analyte, as will the composition of the solid phase (16). Ultra high 
performance liquid chromatography (UHPLC) is a further development of the HPLC 
technique. In UHPLC mobile phase pumps can withstand a higher backpressure, and the 
limitations to particle size and column length can be extended. The particles of the solid phase 
are smaller and more spherical, and the diameter of the column is often smaller than in HPLC. 
This gives greater resolution per unit time and narrower peaks. 
Generally the most widespread used is reversed phase UHPLC where the solid phase is 
hydrophobic and the mobile phase polar (16). Reversed phase UHPLC gives a wide range of 
possibilities in composition of both mobile- and solid phase. The mobile phase may vary in 
pH and polarity as suits the analyte. The pH can either be acidic or alkaline throughout the 
analysis, or a pH gradient can be made. The aqueous-to-organic ratio in the mobile phase will 
change according to a preprogrammed gradient. The gradient moves from mainly aqueous to 
mainly organic during the analysis, ensuring a separation of components of the sample. The 
solid phase is most commonly made up from molecules of varying length and hydrophobicity 
linked to a silica core.  
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2.5.2 Electrospray Ionization  
 
Figure 12: Illustration of an ESI z-spray source. Used with permission by Terje Vasskog (17). 
Due to so called soft ionization methods such as matrix-assisted laser desorption ionization 
and electrospray ionization (ESI), which is able to form molecule ions from biologically 
derived samples, MS/MS can be used to analyze peptides, proteins and nucleic acids (18). As 
illustrated in fFigure 12, the mobile phase from the UHPLC flows through a capillary and an 
aerosol is formed with help from a nebulizing gas that flows along the tip of the capillary. 
There is a steel capillary in the continuation of the UHPLC-capillary with an electrical 
potential of up to 5 kV. The electrode, gives an electric potential to the small drops of mobile 
phase in the aerosol. The volatile mobile phase evaporates, and the evaporation is helped by a 
drying gas. After mobile phase evaporation the analyte ions are extracted through the sample 
cone into the vacuum area of the MS (15). 
In ESI, the number of charges a molecule will get depends on its molecular weight and 
number of available potential charge sites. Potential charge sites include sites for protonation, 
deprotonation, anionization and cationization. Since the MS measures a mass-to-charge ratio, 
a high charge state will allow big molecules such as proteins to be analyzed on standard MS 
instruments. Molecules of low mass gives only singly charged ions in ESI. Higher mass 
molecules will form doubly, triply and multiply charged ions that all will show up in the mass 
spectrum of the compound (19). 
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2.5.3 Mass Spectrometry  
 
A mass spectrometer (MS) is an instrument that detects atomic or molecular ions based on 
their mass to charge ratio (m/z). The MS might also form fragment-ions from the original 
molecular ion, which can be used in structure determination of unknown analytes. An 
instrument capable of two stages of m/z analysis is referred to as a MS/MS.  There is a range 
of available systems to combine two MS, here under the tandem Quadropole, Quadropole-
Time-of-Flight (QTOF) and Orbitrap instruments.  
The hybrid MS/MS instrument QTOF is commonly used in MS/MS analysis of peptides. In 
the QTOF the first MS is a quadropole mass filter (MS1), the collision cell is an ion guide of 
some kind (i.e. T-wave collision cell or collision cell consisting of six or eight metal rods), 
and the final mass analysis occurs in a Time-of-Flight MS (MS2) (18). The quadropole in 
MS1 consists of four parallel hyperbolic or round rod electrodes in a square. The opposite 
rods have the same potential at any given time. A periodic voltage is applied to the rods, and 
the ions will be attracted and repulsed accordingly as the electric force changes. In the 
collision cell an inert collision-gas may be present. Argon and Nitrogen are frequently used 
for this purpose. The collision gas fragments the precursor-ions by increasing the internal 
energy of these through collisions. The increased energy breaks the weakest bonds in the 
precursor-ion and form fragments, known as product ions. Finally, the time-of-flight analyzer 
measures, as indicated by the name, the time any given ion uses to move a given distance. The 
principle is that the smaller and therefore lighter ions will reach the detector earlier than the 
heavier ions (19).   
A MS/MS measures the compounds monoisotopic mass, not the average mass usually used 
when calculating molar masses and so on. Peptides and proteins are high mass molecules, and 
often carry multiple charges due to alkaline side-chains of AA. The charge state of an analyte 
ion can be determined by calculating the m/z difference between its isotopic peaks. The mass 
difference between the C12 and the C13 isotopic peak is one amu. At charge state one the m/z 
difference between the isotopic peaks is one. If the charge state is four, the mass difference 




2.5.4 CID-Fragmentation of Peptides 
 
Collision induced dissociation (CID) is a fragmentation method widely used in MS/MS of 
small ions, but has extended to incorporate larger biological compounds (16). 
 CID of peptide-ions is an important tool in MS/MS analysis of peptides. It is a mechanism by 
which to fragment molecular ions by colliding them with inert gas molecules. The kinetic 
energy of the collision results in fragmentation of the precursor-ion (18). A peptide is a chain 
of amino acids (AA) chained together by the peptide bond. The C-terminus of the first AA 
bonds to the N-terminus of the second, creating a water-molecule and a covalent bond 
between the two AAs. When this AA-chain is fragmented, it may break at any bond in the 
peptide back-bone, dependent on the fragmentation technique used. A classification system 
has been made to generalize the names of the fragment-ions that occur. Figure 13 shows a 
peptide chain of n amino acids with the fragment names and numbers according to this 
system. The names and numbering of the fragments follows the sequence of the peptide.  
 
Figure 13: Fragment-ions of peptides. The chain breaks in different positions forming a-x, b-y and c-z fragments. Note 
the two protons added to c- and y-ions.    
In CID-fragmentation, the majority of the fragmentations happen at the amide bond CO-NH, 
which gives dominant b- and y-ion series. Figure 14 shows two residues in a peptide-chain 




Figure 14: Numbering of b and y fragment-ions follows the AA sequence.  
A peptide containing Proline (Pro) will undergo a Proline induced fragmentation. Proline is a 
special case, since its side-chain folds back on its back-bone amide. A Pro-residue will 
therefore bend the peptide back-bone differently than the other AAs, and stabilize the fold of 
the native isomer of the peptide. When the peptide is linearized, this bend will destabilize the 
structure, and fragmentation will occur more frequently at this residue than other residues in 
the sequence. The peptide will fragment on the N-terminal side in a Pro-residue. The resulting 
y-ion will most likely be the base peak in a MS/MS spectrum.  
 
2.6 Software Mediated Structure Determination   
 
To be able to interpret the signals from the MS/MS and determine the disulfide-bridges, the 
sequence of the linear peptide and the monoisotopic mass of the chosen alkylating agents has 
to be known. There are several databases that offer help to interpret the MS/MS output and 
thus structure determine proteins and peptides. Amongst these is “Protein prospector”. The 
database is programmed to calculate theoretical masses of fragments arising from CID-
fragmentation of the peptide. On the front page of the Protein prospector database there are 
links to underlying pages such as “MS-digest”, “”MS-fit” and “MS-product”. These pages use 
different software to calculate fragments. “MS-digest” for instance, calculates fragments 
made from digesting the peptide with digestive enzymes such as trypsin. “MS-product” is 
used to calculate CID-fragments, and the known peptide sequence is manually submitted to 
the database using the one-letter abbreviations of the amino acids. Since the program 
calculates theoretical masses of fragments, it needs information on whether or not the C-
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terminal is amidated. Protein prospector allows adjustments in the peptide-chain by 
exchanging residues in the sequence with the small letters u, v, x and y. These substitute 
residues needs to be manually defined in the database, by submitting monoisotopic masses 
and molecular formulas.  
In the case of a peptide with four Cys-residues and two bridges, two and two Cysteines will 
be alkylated with the same alkylating agents. The small letters will correspond to an alkylated 
Cys-residue, and monoisotopic masses of the alkylated Cys-residues needs to be allocated to 
the small letter of choice. Following the theoretical fragmentation in Protein prospector, the 
theoretical fragment-masses can be compared with the masses of the actual fragments that 
were formed in the collision cell of the MS/MS. Since there are three possible isomers of a 
peptide with two disulfide-bridges, all three possibilities needs to be submitted to the database 
and compared with the actual fragments to decide which isomer is the one at hand. If the 
native AAs are left out of the sequence, the three isomers can be illustrated by the letter 
combinations vvuu, vuvu and uvvu in the database. Uuvv is the same isomer as vvuu and is 
not submitted to the database. The same situation is valid for uvuv and vuuv, which are the 
same as vuvu and uvvu respectively. These letter combinations will be used to illustrate the 
three isomers throughout this study. 
Not all of the ions made from CID-fragmentation will be helpful towards identifying the fold 
of the DRP. If an ion can assist in identifying the fold, it is called a diagnostic ion. To be a 
diagnostic ion, the fragmentation of the sequence has to separate the four Cys-residues. A 
fragment containing one to three Cys-residues is therefore a diagnostic ion.  
The MS/MS spectra are compared to the three possible isomers, and diagnostic ions are 
found. To conclude on an isomer, at least two diagnostic fragment-ions per bridge are needed. 
A total of six diagnostic ions in the case of a peptide with two disulfide-bridges are sufficient 




3. Aim of the Thesis 
 
The aim of this thesis is to find a method to determine which Cysteine residues are linked by 
disulfide-bridges in a disulfide-rich bioactive peptide with three or more Cysteine residues. 
This will be done by reducing commercially available disulfide-rich peptides one disulfide-
bridge at the time, followed by alkylation of the different bridges with different maleimides. 
The reduced and alkylated peptide is then analyzed on an UHPLC-MS/MS and the bridges 
allocated by alkylation. The final structural determination is accomplished by software 
analysis of the MS/MS chromatograms. The method will be tested on different commercially 
available disulfide-rich bioactive peptides with different sequence-length and number of 
disulfide-bridges. Finally, the method will be used to verify correct bridging in a self-
synthesized peptide.   
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4. Methods and Materials 
4.1 Chemicals 
 
For the reduction- and alkylation steps of the different peptides Tris(2-
carboxyethyl)phosphine (TCEP), N-methylmaleimide(NMM), N-ethylmaleimide(NEM), 
Phenylmaleimide (PhM), tert-Butylmaleimide(tBM), 5,5’-dithiobis(2-nito-benzoic acid) 
(DTNB) from Sigma Aldrich, St Louis, MO, USA were used. Conotoxin α  ImI and 
Conotoxin ω GVIA was purchased from Tocris bioscience, Bristol, UK. TCEP and the 
peptides were buffered with ammonium formate buffer with with pH 3, made from ammonia 
solution 28-30 % for analysis and formic acid 98-100 % for analysis both from Merck, 
Darmstadt, Germany. The acetonitrile (AcN) used was HiPerSolv Chromanorm Acetonitrile 
lc-ms grade from BDH Prolabo, Leuven, Belgium. Purified water was obtained from a Rios 
100 milliQ purification unit from EMD Millipore corp, Billerica, MA, USA, hereby referred 
to as simply milliQ water.  
In the synthesis of Conotoxin α-ImI,  the protected amino acids Fmoc-Gly-OH, Fmoc-
Cys(trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asp(otBu)-OH, Fmoc-Pro-OH, Fmoc-Arg(pbf)-OH, 
Fmoc-Ala-OH, Fmoc-Trp(Boc)-OH and Fmoc-Cys(Acm)-OH were used to build the 
peptides.  The peptide chain was built on a Rink Resin SS, 100-200 mesh, 1 % DVB from 
Advanced Chemtech, Louisville, KY, USA. Acetic anhydride, Piperidine 99%, 
triisopropylsilane (TIS) and Dichloromethane (DCM) was purchased from Sigma-Aldrich, St 
Louis, Missouri, USA. Merck Schuhardt OHG, Darmstadt, Germany produced the 2, 4, 6-
trimethylpiridine for synthesis (TMP), the O-(1H-6-Chloro-benzothiazole-1-yl)-1,1,3,3-
tetramethyl-uronium-hexafluoro-phospate (HCTU), and the 22rifluoroacetic acid for synthesis 
(TFA) used. Formic acid 98 – 100 % for analysis (FA) and N, N-Dimethylformamide (DMF) 
was also obtained from Merck. Finally, N, N-diisopropylethylamine (DIPEA) came from 






The main analysis of the peptides was performed on an Acquity UPLC I-class with an 
Acquity UPLC BEH C18 1.7 µm 2.1*100 mm column for the first 5 months and an Acquity 
UPLC BEH C18 1.7 µm 2.1*150 mm column for the remaining period. The detector coupled 
to the UHPLC was a Xevo G2 QTOF MS. All instruments and columns above are from 
Waters corp., Milford, MA, USA. For the activity studies of TCEP an Agilent tech open-top 
UV quarts cell 10 mm, 3 mL vol. in a UV spectrometer from Agilent Technologies, Santa 
Clara, CA, USA, was used. The maleimides were analyzed on an Acquity UPLC BEH C18 
1.7 µm 2.1*50 mm column in an Acquity UPLC H-class connected to a UPD pda detector, all 
from Waters corp. The same instrument was used to separate the peptide with two alkylated 
sulfhydryl-groups from the unreacted peptide still present in the sample.  
For the solid phase extractions (SPE), Solid Phase Extraction Cartridge; Empore C18 
Standard density from 3M Company, St. Paul, MN, USA on a vacuum manifold from Thermo 
Fisher Scientific, Waltham, MA, USA was used.   
A Prelude Peptide Synthesizer version 2.1.0.192 from Protein Technologies Inc., Tucson, AZ, 
USA, performed the peptide synthesis. Solvent was evaporated from the synthesized peptides 
with a Hei-VAP Advantage rotavapor from Heidolph Instruments GmbH & co, Schwabach, 
Germany. The peptide crudes were purified on an Xselect csh prep C18 5µm OBD 19*250 
mm column in a Waters 2545 Binary Gradient Module with a 998 pda detector from Waters 
corp., Milford, MA, USA, and the fractions were gathered on a Waters fraction collector 
model 2767 Sample Manager from the same provider. Freeze-drying was performed on a 
FreeZone 4.5 plus from Labconco, Kansas City, MO, USA. 
The UHPLC-MS/MS system, the HPLC-PDA fraction collector system and the UHPLC-PDA 
were controlled and operated by the software MassLynx version 4.1 copyrighted by Waters 
corp., Milford, MA, USA. The operating system for the Prelude Peptide Synthesizer was 
SUser version 2.1.0.391copyrighted by Protein Technologies Inc. The peptide-models were 
drawn in the educational version of Pymol Molecular Graphics System version 1.3 
copyrighted by Schrodinger LLC. Molecular structures and reaction equations are derived 
from the database http://www.chemspider.com  provided by the Royal Society of Chemistry, 
or drawn with the freeware ChemSketch version 14.01. Paint version 6.1 has been used to add 
information to structures and chromatograms. The monoisotopic masses were calculated by 
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use of the web page http://www.lfd.uci.edu/~gohlke/molmass/, a freely available molecular 
mass calculator developed by Christoph Gohlke, Laboratory for Fluorescence Dynamics, 
University of California Irvine.  The database 






4.3 Peptide Synthesis 
 
Fmoc-SPPS was chosen as method to synthesize the conotoxins because it demands less use 
of TFA than Boc-SPPS, and anhydrous hydrogen fluoride is avoided altogether. The synthesis 
was set at 100 mM scale using Fmoc-amino acids dissolved in N, N-dimethylformamide 
(DMF) with a concentration of 200 mM. A rink resin with a loading capacity of 0.7 mmole/g 
was used as solid phase. It is important that the resin is swelled in DMF prior to the first 
coupling. The swelled resin has an increased number of binding sites accessible to the first 
residue in the process, compared to the compact, non-swelled resin.                                                                                                                         
O-(1H-6-Chloro-benzothiazole-1-yl)-1,1,3,3-tetramethyl-uronium-hexafluoro-phospate 
(HCTU) was used as a activator in the coupling step due to its fast reaction time and ability to 
produce higher purity peptides than HBTU (20). N, N-diisopropylethylamine (DIPEA) was 
used as base. Base is used together with the activator to ensure an in situ activation of the 
carboxylic acid, the formation of an ester and thus a fast and complete coupling reaction. The 
coupling step was repeated for each Fmoc-amino acid. This is referred to as a double 
coupling, and increases the yield of the synthesis.      
A mixture with a 1:1:3 ratio of acetic anhydride: pyridine: DMF capped the unprotected, thus 
uncoupled amino-acids, to prevent peptides with residues missing in the sequence being 
synthesized.  
Two protection groups were used on the Fmoc-Cysteine; Trt and Acm. In the case of Cα, Cys-
2 and Cys-8 were protected with Trt, and Acm was used to ensure formation of the native 
bridge between Cys-3 and Cys-12.  
Since residue 5 in Cα is Aspartic acid, steps must be made to prevent aspartamide formation. 
Instead of using 20 % piperidine in DMF as is customary, 20 % piperidine in DMF with 5 % 
FA was used as a deprotecting agent, since this has been proved to be effective (21).  
Actions were taken to prevent racemization of Cysteine. The Fmoc-Cys(Acm)-OH was 
dissolved in 47 % dichloromethane (DCM) in DMF since racemization occurs more 
frequently in polar solution (22). This was done by dissolving the Fmoc-Cys(Trt)-OH and 
Fmoc-Cys(Acm)-OH and the base used under the coupling step in a mixture of nonpolar 
DCM and polar DMF as described in Table 3. The protected Cys-residues were first dissolved 
in 1000 µL pure DMF before DCM was added due to their poor the solubility in DCM. 
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Table 3: The volume of DMF and DCM used in the different solutions during the coupling of Cysteine 
 DMF(µL) DCM(µL) 
HCTU 1300      0 
TMP   250   750 
AA 1000 1500 
Total 2550 (53 %) 2250 (47 %) 
 
The base used in the coupling reaction together with HCTU was changed from the usual 
DIPEA to a weaker base, namely 2, 2, 6, 6-Tetramethylpiperidine (TMP), for the coupling 
step of the Fmoc-Cysteine. This was also a step towards preventing racemization (22).  
After each step, the resin with the growing peptide-chain attached was washed with DMF to 
remove excess reagents.   
The assembly of the peptide was automated, and the Prelude was programmed to perform all 
the wanted steps. Four different coupling programs were used to accommodate for the needs 
in the different coupling stages. The first coupling is different from the others since it involves 
the resin swell step at the beginning of the sequence. The standard program used for the 
standard amino acids starts with removing the Fmoc on the N-terminus of the already coupled 
amino acid, readying it for the next coupling. This program was repeated until the next amino 
acid was a Cysteine, a Lysine or simply the last amino acid of the peptide chain. Since there 
are some considerations to be made during the coupling of Cysteine residues, a special 
program was made just for this coupling. The difference for the Prelude is the base used 
during the coupling. It was changed from the strong base DIPEA to the weak base TMP. The 
final coupling was made by yet a different program. A deprotection step at the end of the 
sequence is added to remove the final Fmoc; the other steps are identical to the standard 
coupling program. The different programs may be viewed Appendix 1. 
The cleaving was done manually, and the cleaving cocktail consisted of 95% TFA, 2, 5% TIS 
and 2, 5% milliQ water. The resin was kept in 10 mL cleaving cocktail for 3 hours. When the 
cleaving was completed, the peptide was isolated by filtration. The linear, unprotected peptide 
was transferred to a round bottom flask. Ether was added and the peptide was left to 
precipitate. After precipitation, the ether was decanted away, and the precipitate was air dried. 
The crude peptide was re-dissolved in milliQ water with 0.1 % v/v TFA after weighing. 
27 
 
 The quality of the crude was analyzed on an analytical HPLC instrument, and a standard inlet 
method with milliQ water as mobile phase A and AcN as mobile phase B both with 0.1 % v/v 
TFA was used. A linear gradient of 0-50 % of mobile phase B (AcN with 0.1% TFA) for 30 
minutes was used for the preliminary analysis. The analysis is performed to verify the quality 
of the crude and to find the retention time of the crude. The retention time was used to 
program the preparative HPLC by which the crude peptide was purified. Purification 
chromatography was performed using a linear gradient of 5-35 % mobile phase B over 30 
minutes, followed by a column rinse with 100 % B for 5 minutes and finally a 4 minute re-
equilibration down to 5 % B before the next sample was run.  
The purified peptide solution was then freeze-dried, weighed and subsequently re-dissolved in 
the mobile phase A described above. The purification step was repeated to ensure a purity of 
95% or higher. If the crude did not meet this standard, a new purification step was initiated. 
The fractions were analyzed on an UHPLC-PDA instrument and fractions with a purity of 95 
% or higher were pooled. The pure linear peptide with two Cys-residues still protected by 
Acm, was then oxidized. 
Chemical oxidation was chosen over air oxidation to ensure the correct fold on the finished 
product. When a peptide is oxidized by chemical oxidation the method must be divided into 
separate oxidizing steps, one for each bridge. In the case of Cα with two bridges, two steps 
must be made. The first step oxidizes the Trt-protected Cys-residues. The Trt-group was 
removed during cleaving, and the Cys-residues two and eight are left deprotected. The freeze-
dried linear peptide was dissolved in mobile phase A (milliQ water with 0.1% TFA). 
Ammonium acetate buffer pH 7 was stirred by a magnetic stirrer in a conical flask. The 
unreduced, linear peptide was dripped in to the buffer one drop at the time and the 
concentration of the linear peptide in the buffer solution was 0.1 mg/mL, both measures taken 
against dimerization. The linear peptide was left to air-oxidize to monocyclic in the buffer 
overnight, and the oxidation was confirmed by UHPLC-PDA and MS. 
The second bridge was oxidized by adding 10 molar equivalents of iodine to the monocyclic 
peptide. Iodine has a dual quality, as it both deprotects the Acm-Cys residues and oxidizes the 
free Cys residues 3 and 12. 50 mM iodine solution was made of I2 dissolved in Acetic Acid. 
The iodine-peptide solution was left to react while stirred under N2 –gas. Samples were taken 
after 0, 10, 20, 30, 50 minutes and analyzed with UHPLC-PDA. The oxidation was duly 
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stopped by adding ascorbic acid to the iodine-peptide solution when the peptide was fully 
cyclic. The oxidized peptide was freeze-dried and kept in an air tight container at -20ºC. 
Both the freeze-drying steps and the chemical oxidation were performed by my fellow student 
Børge Renmælmo, and the methods are merely recited here with his permission. 
 
4.4 Activity Studies of TCEP 
 
2 mM solution of DTNB and five 4mM TCEP solutions were made in milliQ water. The five 
4 mM TCEP solutions were pH adjusted to pH 2, 3, 4, 5 and 6. The pH adjustment of the pH 
2 TCEP solution was performed with FA, and the solutions with pH 3, 4, 5 and 6 were made 
with 1 M sodium hydroxide (NaOH). Since the UV quartz-cell has a volume of 3 mL and 
needs to be filled to at least two thirds of this volume to make an accurate measurement, 
milliQ water was added to obtain a volume of 3 mL in each sample.  
Neither the DTNB nor the water was pH adjusted. The DTNB:TCEP ratio was 1:1. The 
contents of the test tube were immediately transferred to a quarts cell, and the absorbance of 
the DTNB-TCEP mixture was measured after 0, 15 and 30 minutes. Three parallel samples of 
DTNB:TCEP for each pH was analyzed, a total of 15 samples. Each sample was measured 
three times, and an average of these was calculated. An overview of the concentrations and 
volumes of the 15 samples is presented in Table 4.   
Table 4: Concentration (mM), volume (mL) and pH adjustment of the reagents involved in the activity studies. 
 Concentration (mM) Volume (mL) pH adjusted 
DTNB 2 0.50 No 
TCEP 4 0.25 Yes 
milliQ water - 2.25 No 
 
In the second study, different ratios of DTNB:TCEP were studied. The pH of the 4 mM TCEP 
solution was adjusted to 4 with NaOH, and the absorbance of the DTNB-TCEP mixture was 
measured after 0 and 15 minutes. As in the previous experiment, TCEP was added to a 
reagent glass where DTNB and milliQ water in the amounts described in Table 5 were already 
added, and the absorbance was measured for the first time immediately after the TCEP was 
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added.  Three parallel samples of each ratio were made, and the ratios of DTNB:TCEP 
analyzed were 1:2, 1:5 and 1:10. The absorbance of each sample was measured three times in 
a row and an average was calculated. 
Table 5: Volume of each reagent (mL) in the different ratios measured 
Ratio DTNB:TCEP 1:2 1:5 1:10 
2 mM DNTB (mL) 0.25 0.25 0.25 
4 mM TCEP (mL) 0.50 1.25 2.5 
milliQ water (mL) 2.25 1.50 0.25 
 
4.5 Reduction and Alkylation of Disulfide-Bridges 
 
TCEP was chosen over DTT as a reduction agent since it has been proven to be more 
effective. It is claimed to be active at pH 1 to 12, while DTT has a more limited pH span. In 
addition TCEP reacts solely with the disulfide bond, leaving other side chains unreacted (11). 
To rationalize the project, a TCEP stock-solution with pH 5.5 and concentration 37 mM in 
milliQ water was made to fit the concentration of the peptide solution. A 37 µM solution of 
peptide gave an adequate signal on the MS instrument, but further dilution of the sample had 
to be avoided. By making a 37 mM TCEP stock-solution that could be diluted with milliQ 
water to the wanted concentration every morning, a TCEP-to-peptide molar ratio of 1:1 could 
be made and excessive dilution of the sample avoided. NaOH was added to the TCEP solution 
to acquire pH 5.5, since the pH of the 37 mM TCEP in milliQ water was 2.5. The stock-
solution was divided into 1 mL units in Eppendorf-tubes and kept in the dark at -20ºC. This 
stock-solution was diluted to fit the TCEP-to-peptide ratios to be examined. After three 
weeks, the reduction-results were no longer reproducible, and it seemed as the TCEP stock-
solution had deteriorated in the freezer where it was kept. The TCEP stock-solution was 
therefore discarded, and a fresh TCEP solution was made at the beginning of each day. 
At the beginning of the method development the TCEP solution with pH adjusted to 5.5 was 
used, as earlier research on the area indicated that this would be optimal (10). The reduction 
was more or less instant at this pH, and a TCEP-to-peptide ratio was the parameter that could 
be changed and optimized. Ratios 1:1 through 10:1 were tested. A 1:1 ratio was supposed not 
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to be enough to reduce the disulfide-bridges sufficiently, and a 10:1 ratio to be an excess and 
possibly lead to full reduction of all disulfide-bridges. The TCEP, dissolved in milliQ water 
and with pH adjusted to 5.5, was added to a vial already containing a 37 µM peptide solution. 
The peptide was dissolved in milliQ water without any pH adjustment. Immediately after 
adding TCEP, the mixture was analyzed on the UPHLC-MS/MS instrument. As anticipated, 
1:1 failed to reduce the peptide when the reaction time was less than one minute, and 10:1 
reduced both disulfide-bridges instantaneously. The optimal value was thought to be between 
3:1 and 5:1. Ratios 3:1, 3.5:1, 4:1, 4.5:1 and 5:1 were analyzed to find the best ratio to cleave 
only one disulfide-bridge. However, all ratios examined to this point had three peaks in their 
chromatograms with an m/z corresponding to one cleaved and one intact disulfide-bridge. The 
non-native isomer, not present in the original Cα sample, was now present. This meant that 
the native isomer was rearranged into a non-native isomer during the reduction step. To avoid 
the formation of this non-native isomer, lower ratios and higher reaction times were 
examined. A sample was made with a 1:1 ratio to be injected into the UHPLC-MS/MS system 
every 12 minutes. The non-native isomer was already formed after 12 minutes, and a new, 
shorter UHPLC method was made to be able to follow the reaction more closely. The method 
had the same linear gradient as the 12 minutes method, but was shortened to four minutes 
with a reset period for the gradient of one minute. The sample could then be analyzed every 
five minutes. It became clear that the non-native bridge would appear at any ratio, and 
reaction time did not alter this. The only parameter left was the pH, which led to disregarding 
the previous assumption of the optimal pH value being 5.5. When a disulfide-bridge is 
broken, the sulfhydryl-group of the Cysteine side-chain will be protonated at low pH, and 
deprotonated at high pH. The pKa value of the sulfhydryl side chain of Cysteine is 8.33, and 
its isoelectric point (pI) is 5.02 (23). The local environment may induce abnormal pKa-values, 
and the theoretical pKa value does not give an accurate account for the chemical environment 
in the peptide chain.   
Deprotonated sulfhydryl-groups might react with remaining bridges, breaking these and form 
new, non-native bridges. This is referred to as disulfide scrambling. This is highly 
disadvantageous since the aim of the thesis is to prove correct bridging in a synthesized 
peptide. It was therefore paramount to the study that the regrouping and formation of non-
native bridges was avoided. This was ensured by buffering both TCEP and peptide-solutions 
to pH 3, where the sulfhydryl-groups were in a less reactive state. TCEP was therefore 
dissolved in an ammonium formate buffer with pH 3, as was the peptides. To make sure the 
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reaction terms were stable, TCEP was made fresh every morning. The pH of the buffer was 
regularly measured to ensure a stable pH. 
When the pH was adjusted to 3, both the ratio and the reaction time had to be reexamined. 
Since none of the available literature on TCEP as a reduction agent concerned itself with 
reduction of one disulfide-bridge but rather high excess of TCEP to reduce all disulfide-
bridges in large proteins as a help in sequencing these, ratios in the order 1:1-10:1 were not 
thoroughly described. One paper concluded that TCEP was active at pH 1-12 (10). Since there 
was no evidence of the contrary, the experiments at pH 3 continued where the pH 5.5 
experiments had ended; with a TCEP-to-peptide ratio between ratio 3:1 and 5:1. This turned 
out to be far too low because the reactivity of TCEP proved to be much lower at lower pH. 
Each ratio was examined with the four minutes method and the 12 minutes method. A sample 
was injected from the same vial several times in a row in order to examine the reaction time. 
When it became apparent that the ratio had to be higher, the ratios 10:1, 20:1 and 30:1 were 
examined in the same manner, and also turned out to be too low. Subsequently the ratios 50:1, 
100:1, 200:1 and 300:1 were then analyzed. When the optimal ratio was found, the exact 
reaction time had to be investigated. It seemed as the optimal reaction time would be 
somewhere between four and eight minutes based on the four minutes UHPLC method. The 
TCEP was added to the vial already containing the peptide solution and was analyzed with the 
four minutes method after one minute. Other samples were analyzed after two, three and four 
minutes reaction time to best pinpoint the optimal reaction time. 
 
4.5.1 In-Vial Reduction and Alkylation  
 
The activity of TCEP depends on pH and concentration (11). Low pH requires higher 
concentration and longer reaction times. The optimal ratio between TCEP and the peptides 
with two disulfide-bridges was 100 molar equivalents of TCEP to one mole of peptide. Six 
minutes reaction time was found to be optimal.  
The maleimides were dissolved in AcN to avoid unwanted reactions between maleimides and 
methanol/water. Since the maleimides react with TCEP (13), the TCEP was left to react with 
the peptide for six minutes before PhM was added at 450  molar equivalents of the peptide. 
Even though maleimides instantly and completely react with the available sulfhydryl groups 
at pH 6-7, this proved not to be the case at pH 3. The maleimides are still able to fully alkylate 
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the sulfhydryl-groups, but a longer reaction time is needed. 24 minutes was found to be an 
adequate reaction-time, after analyzing the PhM treated reduced peptide solution with the four 
minutes UHPLC-MS method. A sample was drawn from the vial every five minutes for 30 
minutes. See Table 6 for the optimal values of the parameters in the reduction and following 
alkylation of the two sulfhydryl-groups involved in the first disulfide-bridge. 
Table 6: First step of the reduction and alkylation; reducing one bridge in Cα with TCEP and alkylating it with PhM; 
Amount of reagent in nmole, concentration of the reagents in mM, volumes in µL and reaction times in minutes;                                                        










Cα dissolved in buffer 2.22 0,037 60  
TCEP dissolved in buffer 222 37 6 6 
PhM dissolved in can 1000 100 10 24 
 
For reasons discussed in chapter 5.3, a separation technique was needed to isolate the partially 
reduced and PhM-alkylated peptide. A manual isolation method was developed on an 
UHPLC-PDA instrument. The peptide with one of the two disulfide-bridges reduced and 
alkylated had a retention time of 2.17 on the UHPLC-PDA instrument. Injection volume was 
10 µL, and the mobile phase was manually collected in a vial when the signal appeared on the 
real time chromatogram after 2.17 minutes. The peak width of the correct fraction was 3.6 
seconds. To ensure sufficient amount of the PhM-alkylated peptide, the wanted fraction of six 
injections were gathered in the same vial. Approximately 216 µL were collected (6* 36 µL), 
based on peak width and mobile phase flow. The collected sample was heated to 50 ºC under 
a flow of nitrogen to evaporate AcN to further increase the concentration of the peptide 
solution. The precise amount of peptide present in the sample at this time was not known, but 
an approximate estimate can be made taking mobile phase flow, injection volume, sample 
concentration and peak width into consideration. After six injections an estimate of the 
amount of the peptide with one disulfide-bridge reduced and alkylated with PhM collected 
was 0,58 nmole, and the concentration of the collected sample after volume reduction was 
estimated to  4.5 µM .     
As there was no need to adjust TCEP concentration to avoid unwanted reduction in the second 
step, a vast molar excess of TCEP was added to the partially reduced and PhM-alkylated 
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peptide. A 100 mM solution was made to avoid dilution of the sample; six µL 100 mM TCEP 
gives a molar excess of more than 1000. The reduction of the second bridge was much slower 
than was the case with the first bridge, even with a molar excess of more than 1000 of TCEP 
present. The alkylation step also took considerably longer in the second step than in the first.  
Because of the reaction between TCEP and the maleimides, the second alkylating agent, 
NMM, had to be added in molar excess to the TCEP present. Due to the vast amount of TCEP 
present after the second reduction step, a 0.5 M NMM in AcN solution was made to avoid too 
much dilution of the sample. This gave over 8 times molar excess of NMM to TCEP in the 
sample. Table 7 shows the optimal parameters for the second step of reduction and alkylation. 
Table 7: Second step of the reduction and alkylation; reducing remaining bridge in Cα-PhM2 with TCEP and 
alkylating it with NMM; Amount of reagent in mmole, concentration of the reagents in mM, volumes in µL and 










Cα-PhM2 Ca 0.00058 Ca 0.0045 Ca 130  
TCEP dissolved in buffer 0.6 100 6 120 
NMM dissolved in AcN 5 500 10 60 
 
4.5.2 Reduction and Alkylation on SPE-Column 
 
A second method involving reduction of one disulfide-bridge on a reversed phase SPE-
column was also initiated. The promising results from the first step of investigating whether it 
would work as a generic method for determination of disulfide bridges in DRPs could never 
be followed through, due to failure of the UPLC-MS/MS instrument available. Although the 
most common use of SPE is to extract or purify samples, the main purpose in this thesis was 
to stabilize the fold of the peptide while reducing the disulfide-bridges and thereby enabling 
specific reduction of one disulfide-ridge at the time. The SPE-method is represented in tabular 




Table 8: Reduction of the first disulfide-bridge, generic SPE method; Name of compound, volume of compound in µL, 
and purpose of the chemicals on the SPE-column  
Compound Volume (µL) Purpose 
MeOH 1000 Conditioning 
MilliQ water with 0.1% FA 1000 Equilibration 
Peptide-solution 60 Analyte 
TCEP in ammonium formate buffer pH 3 





Ammonium formate buffer pH 3 5000 Wash 
80% AcN with 0.1% FA 500 Eluting solvent 
 
A conditioning and equilibration must always be done prior to sample loading to ready the 
column for sample loading. After the initial preparation of the column, the sample was loaded 
to the C18 column. The samples were small, 60 µL of 37 µM Cα and 33.7 µM Cω, and it was 
difficult to see if it was loaded onto the solid phase of the column, or was still lingering on top 
of the filter. If the peptide failed to pass the filter, it would be reduced pre-column when 
TCEP was added. To minimize possible pre-column reaction between peptide and TCEP, the 
100 mM TCEP solution was added in two steps. The flow was approximately 1 mL per 30 
seconds for all the following steps. First one mL was loaded and pulled through the column, 
before four more mL of 100 mM TCEP was washed through. Five mL of ammonium formate 
buffer with pH 3 was sent through the column to wash away as much of the TCEP as possible. 
The sample was eluted with an 80% AcN solution with 0.1% FA, and the eluate was collected 
in an Eppendorf tube containing 50 µL 100 mM PhM. Some of the TCEP still remained on 
the column after the washing step and was co-eluted with the peptide. The PhM would quench 
the TCEP and by doing so stop the ongoing reduction of the peptide. To ensure alkylation of 
the disulfide-bridge of the peptide, a molar excess of PhM to TCEP had to be added. No 
calculation was made on how much TCEP was still present in the eluate. 5 µmole of PhM was 
enough to ensure both quenching and alkylation. To concentrate the peptide sample, it was 
heated to 50ºC under nitrogen gas to evaporate AcN. As PhM is poorly soluble in water, 
unreacted PhM precipitated when the AcN evaporated and the relative water content of the 
sample increased. The Eppendorf tube containing the sample, cooled to room temperature 
after volume reduction, was centrifuged and the supernatant collected for analysis. The PhM 
pellet was discarded.  
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4.6 UHPLC-MS/MS  
 
Liquid chromatography was performed using a linear gradient of 5-95 % mobile phase B over 
10 minutes with a 2 minute reset period down to 5 % B before the next sample was run. A 
standard inlet method with milliQ water as mobile phase A and AcN as mobile phase B, both 
with 0.1 % v/v FA, was used. Midway through the project a column change was made from a 
C18 1.7 µm 2.1*100 mm to a C18 1.7 µm 2.1*150 mm. The mobile phase flow was set to 0.6 
mL/minute on the 100 mm column and 0.5 mL/minute when the 150 mm column was used.  
The mass spectrometer was equipped with an ESI ion source and operated in positive mode 
with lock-spray activated.  The lock-spray compound was Leucine enkephalin with a 
monoisotopic mass of 555.269287 Amu (24), which has a signal of 556.2771 m/z in the MS 
software when operated in positive mode.   
The values of several parameters were defined in the MS/MS software. Both low and high 
mass limits had to be defined. The scan time was set to 0.2 seconds to ensure sufficient 
amount of scans over the peaks. The lock-spray scan time determined how often the 
instrument would correct its measurements to the lock-spray compound and adjust the 
measured m/z values accordingly. A capillary voltage of 0.6 kV on the ESI-capillary was 
optimal to ionize the analyte. The desolvation gas was N2 at a temperature of 350 ºC and a 
flow of 800 L/Hour. A cone gas flow at 20 L/Hour, and a cone voltage of 35 V was used. The 





Table 9: Parameters in the MS method; low and high mass (amu), scan time and lock-spray interval (sec), capillary 
voltage (kV), Cone voltage (V), source and desolvation temperature (ºC), cone gas flow and desolvation gas flow 
(L/Hr) and polarity 
Parameters Values 
Low mass 105 
High mass 5000 
Scan time (sec) 0.2  
Lock-spray interval (sec) 15 
Capillary voltage (kV) 0.6 
Cone voltage (V) 35  
Source temperature (ºC) 130 
Desolvation temperature (ºC) 350 
Cone gas flow (L/Hr) 20 
Desolvation gas flow (L/Hr) 800 
Polarity Positive 
 
The final product was analyzed using both mass filters of the MS. In addition to the 
parameters described in Table 9, some additional MS/MS parameters had to be defined. The 
values of these are listed in Table 10. The high and low limits for masses were set lower for 
the MS/MS method, since the peptides would undergo CID-fragmentation. A narrower mass 
window led to the ability to apply a shorter scan time. The instrument was set to switch from 
MS to MS/MS at a total ion count of 2500 per second, and to switch back from MS/MS to MS 
when the signal dropped to a total ion count of 35, or after 1.5 seconds if the signal continued 
beyond this time limit. The charge states selected were the ones with the highest intensity 
signals (total ion count) in the MS analysis of the peptides. Argon was the collision gas of 
choice, and the MassLynx default settings for the charge state recognition and ramping 
collision energy method were used. The collision energy parameters and their values may be 





Table 10: Parameters in the MS/MS method: low and high mass (amu), scan time (sec), Threshold for MS/MS 
acquisition and stop (TiC or sec), selected charge state  
Parameters Values 
Low mass (amu) 80  
High mass (amu) 2000  
Scan time (sec) 0.036  
Threshold for MS/MS acquisition (intensity (total ion count)) 2500  
Threshold for MS/MS stop (intensity (total ion count),  
or elapsed time (sec)) 
35  
or 1.5  
Selected charge state 2+, 3+, 4+ 
 
Several adjustments may be implemented to the MS/MS method in order to optimize it to the 
analyte in question. The aim of the thesis was to make a generic method for all DRPs. The 
interesting task at hand was not to adjust the method to fit Cα perfectly, but rather finding an 
adequate method to be applied on additional peptides.  
The spectra obtained on this MS/MS method, was analyzed with structure determining 
software according to the method below to affirm that the native fold had been synthesized. 
 
4.7 Structure Determination 
 
Collision induced dissociation is the present method of choice for peptide sequencing when 
using a MS/MS instrument, and was therefore chosen for this thesis (25). The database 
“Protein prospector” and its underlying “MS-product” were chosen as a tool to interpret the 
MS/MS spectra obtained when using the method above.  
As described in chapter 2.6, the Cys-residues of the sequence has to be substituted with one of 
the small letters u, v, x and y. In this thesis, “u” was allocated to Cys-NMM, and “v” to Cys-
PhM. The molecular formulas and monoisotopic masses of “u” and “v” were submitted to the 




Figure 15: Cysteine alkylated with NMM and PhM. Chemical formula, molecular weight and theoretical m/z when     
z = 1. 
 
In the case of Cα, both commercially bought and self-synthesized, the sequences 
GvvSDPRuAWRu-NH2, GvuSDPRvAWRu-NH2, GvuSDPRuAWRv-NH2, 
GuuSDPRvAWRv-NH2, GuvSDPRuAWRv-NH2 and GuvSDPRvAWRu-NH2 were 
submitted to the software. The sequences and how they are related to the three possible 
isomers are illustrated in Figure 16. The monoisotopic masses of the two alkylated forms of 
Cysteine were submitted to the program. Finally, the theoretical CID-fragments were 
subsequently compared to the actual CID-fragmented reduced and alkylated peptide. 
 
Figure 16: The three possible isomers of Cα with six different sequences depending on alkylation of the Cys-residues.  
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5. Results and Discussion 
5.1 Synthesis of Conotoxin Alpha ImI  
 
The automated synthesis of Cα was performed according to the method described in chapter 
4.3. Since the synthesized peptide was linear and the fold of the cyclic peptide could not be 
established until the final analysis of the end product, the peptide was referred to as 
DRP1during the process of synthesis, purification and oxidation.  
The freeze-dried crude product was weighed to 19 mg, dissolved in 2 mL mobile phase A, 
and purified on a prep-HPLC instrument. The purified, linear, freeze-dried peptide was 
weighed to 16 mg, and oxidized by two separate steps.  
The initial oxidizing step, from linear to monocyclic state of the peptide, was performed 
according to the method described in 4.3. An UHPLC-PDA analysis was performed both 
before and after the air oxidation in ammonium acetate buffer pH 7. A difference in retention 
time indicated that the free sulfhydryl-groups of the previously Trt-protected Cys-residues had 
oxidized to form a disulfide-bridge. In Figure 17 the UHPLC chromatogram of samples of the 
peptide taken before and after oxidation is presented. Linear DRP1 and monocyclic DRP1 had 
a retention time of 3.06 minutes and 3.11 minutes respectively. At the time of the second 




Figure 17: Linear DRP1 with retention time 3.06 minutes, and monocyclic DRP1 with retention time 3.11. The 
analysis was performed on the same sample, before and after oxidation. Note that there still were some linear DRP1 





Figure 18 shows the UHPLC chromatograms of samples taken 0, 10, 20, 30 and 50 minutes 
into the iodine oxidation of the second bridge after quenching the iodine with ascorbic acid. 
When ascorbic acid was added to the peptide-iodine mixture, the color of the mixture 
instantly changed from red to blank. The color change was an indicator that the iodine was no 
longer active, but quenched by the ascorbic acid. Figure 18 shows how the monocyclic 
species at time = 0 with retention time 3.06, gradually gets smaller and disappears completely 
after 50 minutes of iodine oxidation. The monocyclic species completely oxidizes into the 
cyclic species with retention time 3.12 within 50 minutes. 
 
 
Figure 18: Chemical oxidation of the second bridge of DRP 1. The monocyclic DRP1 has a retention time of 3.06 
minutes, and the fully oxidized DRP1 has a retention time of 3.12 minutes. The monocyclic DRP1 is almost fully 




5.2 Activity Studies of TCEP 
 
The results of the 1:1 ratio experiment are here presented in Figure 19, and the details of the 
results can be viewed in Appendix 2.   
  
Figure 19: Absorbance of DTNB reduced to NTB by TCEP measured at 412 nm after 0, 15 and 30 minutes. 
  
As seen in Figure 19, the reaction is slower and less of the DNTB is reduced to NTB, the 
yellow-colored product measured at 412 nm in the UV-spectrometer, at a lower pH. This 
slower and less potent reaction was later proven to also be the case for the peptide-reduction.  
 
DTNB was also tested with ratios 1:2, 1:5 and 1:10 with TCEP. The samples were measured 
at 0 and 15 minutes, since it seemed from the previous pH-experiment presented in Figure 19 
that the reaction at ratio 1:1 had run its course after 15 minutes. The pH was adjusted to 4 
since there seemed to be little reduction taking place at pH 2 and 3 in the previous 
experiment. The result is presented in Figure 20 and shows a connection between ratio and 
both speed- and amount of DTNB reduced to NTB. Figure 20 shows that the reaction was 



















Absorbance of DTNB and TCEP at molar ratio 








DTNB measured through change in absorbance. The change in absorbance between 0 and 15 
minutes at ratio 1:10 and 1:5 was insignificant, whilst at ratio 1:2 the absorbance measured 
after 15 minutes was higher than the measurement at 0 minutes. Again, this was also seen to 
be true for the reduction of the peptides.  
 
Figure 20: Absorbance of DTNB reduced to NTB by TCEP at ratios 1:2, 1:5 and 1:10 measured at 412 nm after 0 and 
15 minutes.  
 
As will be discussed further in chapter 5.3, it was necessary to keep the pH in the peptide 
experiments at pH 3, which is shown here to be disadvantageous for the TCEP activity.  Had 
the experiment been performed at pH 3, it is likely that there would have been no difference 
between ratios 1:2, 1:5 and 1:10, and that higher ratios would be needed to get a similar 
outcome. This based on the ratio necessary to partially reduce the peptide presented in chapter 
4.5.  According to Santarino IB, Oliveira SCB and Oliveira-Brett AM who did a study on the 
reduction-qualities of TCEP using DNTB, the reduction of disulfide-bridges at a 1.05:1 ratio 
between TCEP and disulfide at pH 4.5 was completed in one hour. At higher ratios and pH, 



























5.3 Reduction and Alkylation of Disulfide-Bridges   
 
Table 11 shows an overview of monoisotopic masses, m/z and charge states of the analytes in 
this work.  
Table 11: Mono-isotopic masses in amu, m/z of the precursor ion, m/z of base peak in the chromatograms and the 





] m/z of base peak, 
charge state in brackets 
Charge states 
observed 
Conotoxin α ImI 1350.484 1351.4918 676.24 (2) 1, 2, 3 
Conotoxin ω GVIA 3035.155 3036.1628 1013.06 (3) 2, 3, 4, 5 
TCEP 250.0606 251.0684 251.06 (1) 1 
Phenylmaleimide 173.0477 174.0555 174.05 (1) 1 
N-methylmaleimide 111.0320 112.0398 112.03 (1) 1 
N-ethylmaleimide 125.0477 126.0555 125.05 (1) 1 
 
Before any attempt was made to reduce and alkylate the two commercially acquired peptides, 
they were analyzed on the UHPLC-MS/MS. The retention time of the unreacted peptides 
could be used to some extent to predict retention time for the reduced species and the 
alkylated species. It was also interesting to see which charge state was most intense in the 
spectra, and which would be the m/z of the peptide peak in the chromatogram. Figure 21 and 








Figure 22: MS spectrum of Cα. Charge states for Cα; Theoretical values for m/z when [M+H+]= 1351.484: 





Figure 23 and Figure 24 show the chromatogram and spectrum of Cω respectively. 
  
 





Figure 24: MS spectrum of peak 2.36 in the chromatogram of Cω. [M+H+]=3036.155. Charge states for Cω; 
Theoretical values for  m/z when [M+H+]= 3036.155:(3035.155/2) + 1 = 1519.077, (3035.155/3) + 1= 1013.052,  
(3035.155/4) + 1 = 760.039, (3035.155/5) + 1= 608.031. 
 
5.3.1 In-Vial Reduction and Alkylation  
 
After several trials at different pH, ratios and reaction times, the ones described in the method 
development chapter was found to be as good as it could get. When the peptide-reduction was 
performed at pH 5 with four molar equivalents of TCEP, the chromatogram showed five 




Figure 25: Chromatogram of Cα reduced with TCEP at a ratio 1:4 at pH 5. Peaks are numbered as follows: 1: non-
native isomer of Cα formed during reduction 2: Disulfide-bridge 1 in the native isomer of Cα reduced, 3: Fully 
reduced Cα, 4: Unreacted Cα and 5: Disulfide-bridge 2 in the native isomer of Cα reduced.     
 
The base peak of Figure 25, peak number 4, was from the still unreacted Cα.  There was also 
a strong signal from unreacted TCEP, suggesting that given time, the reaction would go 
towards full reduction of both the disulfide-bridges. Even though Cα has two disulfide-
bridges, there were three peaks with the same m/z separated in the UHPLC. These 
corresponds to three different isomers were one bridge is reduced and the other is intact. This 
indicates that the third, non-native isomer is formed through rearrangement during the 
reduction of the first bridge at pH 5, a phenomenon referred to as disulfide scrambling (25). 
According to the pKa value of the sulfhydryl group in Cysteine (8.33), the sulfhydryl-groups 
of the Cys-residues should have been 99 % in its protonated, less reactive state, and should 
not succumb to disulfide scrambling. Since this disulfide scrambling was observed at pH 5.5, 
it is assumed that the local chemical environment of the peptide changes the pKa value of the 
sulfhydryl group in Cysteine in Cα. The fully reduced peptide was also present. The 
chromatographic separation was adequate for the purpose of this project. Figure 26 shows the 
spectra of the three oxidation stages of Cα: The fully reduced, with only one of two disulfide-
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bridges reduced and the native Cα, all with the charge states z = 1, 2 and 3 visible in their 
spectra.  
 
Figure 26: Spectra of the three stages of oxidation for Cα. Fully reduced on top, one reduced disulfide bridge in the 
middle and unreacted, native Cα at the bottom. 
  
To be able to prove that the peptide has the native fold, the formation of the third, non-native 
isomer must be prevented. Hence, the re-oxidation of the non-native isomer that happened 
when a disulfide-bridge was broken at pH 5 had to be avoided. Peak number 1 in Figure 25 is 
the non-native bridge. At pH 3 there were only two peaks in the chromatogram with an m/z 
corresponding to the peptide with one cleaved and one intact bridge, which indicates that the 
re-oxidation does not occur at pH 3. Figure 27 shows the chromatogram for the reaction 




Figure 27: Chromatogram of Cα reduced with TCEP at a ratio 1:100 at pH 3. Peaks are numbered as follows: 1: 
Disulfide-bridge 1 in the native isomer of Cα reduced, 2: Fully reduced Cα, 3: Unreacted Cα and 4: Disulfide-bridge 2 
in the native isomer of Cα reduced.   
 
This is due to the protonation of the sulfhydryl-group. When the sulfhydryl-group is ionic, it 
is highly reactive and will seek to break other disulfide-bridges. By keeping the pH low, the 
sulfhydryl-groups are protonated and rendered less active. Figure 25 and Figure 27 are 
zoomed in images of the peptide peaks in the chromatograms. In addition the TCEP signal 
was present in both chromatograms. The TCEP signal at pH 3 was even higher than at pH 5, 
which is to be expected since the ratio between Cα and TCEP is 25 times higher at pH 3 
compared to pH 5. The full chromatogram may be viewed in Appendix 3.  
At pH 3, the reaction-time and molecular equivalents of TCEP had to be changed. Where at 
pH 5 the reaction was instantaneous, the reaction time necessary to reduce one bridge in Cα at 
pH 3 was 6 minutes. 100 equivalents of TCEP had to be added to the Cα at pH 3 to reduce 
one bridge. This would instantly reduce both bridges at pH 5. When the pH was 5, four times 
TCEP to one Cα was enough.  
Leaving the reaction longer than six minutes at pH 3 did not increase the amount of the 
wanted isomer, it only increased the amount of fully reduced Cα. As peak four in Figure 27 
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did not change significantly between the different analyses taken, it seemed the single bridge 
reduction of the other bridge was stable. This indicates the disulfide-bridge that is reduced 
first is more accessible to the TCEP than the other. Steric hindrance due to the peptide folding 
may be an explanation to this observation. When developing the method, a four minute 
method with a linear gradient from 0-40 % mobile phase B was developed to pinpoint the 
appropriate reaction time. The development of the reaction could be viewed through the 
chromatograms. The intact Cα peak, peak number three in Figure 27, would gradually get 
lower and in the end disappear completely if the reaction was allowed to go far enough. Peak 
number one in Figure 27 appeared first, before peak number two. Peak number one was the 
first, more easily accessed bridge. Number two was the second, more shielded and protected 
bridge that would not be reduced so easily without the first bridge being reduced first. After 
three analyses of the reduction process lasting four minutes, the first peak was stable and 
further reduction only gave more of the fully reduced version. The fifth peak in the 
chromatogram was higher than in the first and second analysis, and if the reaction was 
allowed to continue, all other peaks would disappear, leaving only the fully reduced version 
of Cα.   
After the first reduction stage, the peptide was alkylated. The alkylating agents of choice, 
maleimides, are poorly soluble in water and the solubility decreases with the size of the 
differentiating side-chain. NMM was water soluble, while the other maleimides were all 
readily soluble in the organic solutions of MeOH and AcN. PhM and tBuM reacted with 
water and MeOH when dissolved in a 40:60 solution. The reactions were detected upon 
UHPLC-MS analysis of the maleimides, this data is not shown. AcN was chosen to dissolve 
all maleimides to avoid such reactions.  
Analysis of tBuM on UHPLC-MS/MS indicates that it was not as stable as wanted. Three 
peaks with m/z suggesting tBuM with a missing methyl-group was observed in the 
chromatogram. It seemed as a loss of each one of the three methyl groups in tBuM gave a de-
methylated molecule with different retention-time compared to de-methylation in the two 
other positions. Why this happened is difficult to explain, since the molecular structure of 
tBuM suggests that there is free rotation in the molecule, which would give the same isomer 
regardless of which methyl-group that left the molecule. Regardless of the reason, a 
maleimide that it self produces four signals in a chromatogram  would lead to a messy 
chromatogram of the alkylated peptide where there was a possibility for as many as four 
peaks corresponding to the same product, namely one for the unreacted tBuM and one for 
53 
 
each of the de-methylated states of tBuM. This de-methylation was present both in aqueous 
solution and both organic solutions used in this work.     
Alkylation alters the chemical properties of the peptide and therefore also the retention-time. 
Firstly the alkylation was carried out with NMM. This turned out to be unfavorable, because 
the retention-time for the first Cα with one reduced and alkylated bridge was the same as for 
the second non-alkylated isomer. In addition to this co-elution, the separation between the 
remaining signals was barely acceptable. To shift the signals and thus improve the separation 
the reduced peptide was alkylated with a more lipophilic maleimide, namely phenyl 
maleimide. PhM required extended reaction time compared to NMM to ensure full alkylation 
of the two sulfhydryl-groups in the partially reduced disulfide-bridge. The reaction between 
partially reduced Cα and NMM was completed within 12 minutes. When PhM was added to 
the partially reduced peptide and left in room temperature for 12 minutes, a signal with m/z 
corresponding to Cα with only one PhM bound to it was observed. There was also a signal 
with m/z 624 where z equaled 3. This corresponds to a compound weighing 1873 amu, which 
is Cα with three PhM. This data is not shown. The reaction time was therefore prolonged to 
24 minutes to ensure full alkylation of all available sulfhydryl-groups, thus eliminating the 
signals from Cα with one and three attached PhM. Figure 28 shows the chromatogram of the 
completed alkylation reaction. The chromatogram shows no signals corresponding to 
unreacted TCEP, nor any from PhM. There is however a peak with m/z 424.1452, 
corresponding to the end product of a reaction between the two. This reaction is complete and 
irreversible, and probably fully incapacitates TCEP. It seems that TCEP reaction is more 
favorable for the maleimides, and therefore happens before the desired reaction between the 
maleimides and the reduced peptide. A vast molar excess of maleimide must therefore be 
added to the Cα-TCEP mixture to ensure there is in fact enough free maleimides to react with 




Figure 28: Chromatogram of Cα reduced with TCEP at a ratio 1:100 and alkylated with PhM at pH 3. Peaks are 
numbered as follows: 1: Injection peak, 2: TCEP and PhM reacted, 3: Unreduced Cα, 4: Contamination, 5: Cα with 2 
PhM coupled to the sulfhydryl-group of the Cys-residues formerly attached through a disulfide-bridge, 6: Cα with the 
other disulfide-bridge reduced and alkylated with PhM, 7: Fully reduced and alkylated Cα.   
 
To reduce and alkylate the remaining bridge with another maleimide, TCEP needs to be 
reintroduced. TCEP cannot be added directly to the mixture of Cα in different stages of 
reduction and alkylation presented in Figure 28. The possibility that there was unreacted PhM 
ready to alkylate the next bridge when reduced could not be ruled out, even if there were no 
signal corresponding to PhM in the MS. To avoid a reaction between the sulfhydryl-groups of 
the second bridge and PhM, the Cα with one disulfide-bridge alkylated with PhM needed to 
be separated from the other compounds. This version of Cα will from now on be referred to as 
Cα-PhM2. Peak number 5 with m/z 567.2095 in Figure 28 is Cα-PhM2. An attempt was done 
to separate the compounds on the available prep-HPLC system. The collection of the wanted 
peak was analyzed on the MS/MS, but was too diluted to give a signal, and it was clear that 
this was not the way forward. The separation idea was good, but fruitless since a mobile phase 
flow of 20 mL/min is needed on the available prep-column. A manual separation method on 
an analytical column on an UHPLC-PDA was therefore developed.  
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It was challenging to collect the Cα-PhM2 from the UHPLC-PDA, since there was a delay 
between the peak appearing in the chromatogram and the Cα-PhM2 was actually coming out 
of the tube. The delay corresponded to one drop of mobile phase. A trial analysis with 
MS/MS showed that one run was not sufficient; the concentration of Cα-PhM2 was too low to 
give a signal strong enough for reliable MS/MS results. 6 injections of 10 µL were gathered in 
one vial to ensure a sufficient amount of Cα-PhM2. One injection contained approximately 
0.29 nmol peptide, whereof approximately 25% was Cα-PhM2. The rest of the peptide was 
either still intact or fully reduced and alkylated.    
After gathering the Cα-PhM2 from the UHPLC-PDA, the AcN from the mobile phase was 
removed by heating the sample under nitrogen flow. This increased the concentration of Cα-
PhM2. The concentration and amount of Cα-PhM2 had to be high enough to give adequate 
signals when analyzed with the MS/MS method. 
The actual amount of Cα-PhM2 that was obtained with this method is highly uncertain. Since 
the intention was to fully reduce the remaining bridge, there were no concerns regarding the 
amount of TCEP that was added to Cα-PhM2. To make sure the reduction was complete, 0.6 
µmoles of TCEP was added. To ensure as little dilution of the sample as possible, a 100 mM 
solution of TCEP was made. It was clear that the reaction-time for the reduction of the second 
bridge was much longer than the first. A sample that was run after half an hour showed that 
TCEP failed to fully reduce the Cα-PhM2 during this time. Only after 2 hours was the second 
bridge in Cα-PhM2 fully reduced. It is not clear why this second reaction was slower than the 
first, but it is likely that the steric hindrances of the second bridge, both from the unfolded 
peptide chain itself and the added PhM, play a role.  
Since a vast excess of TCEP was used to ensure reduction, an even greater excess of NMM 
had to be added. This was necessary since the available unreacted TCEP instantly would react 
with available NMM before the NMM could alkylate the peptide. To ensure full alkylation of 
the second bridge, the Cα-PhM2-NMM2 mixture was left for one hour before analyzing it with 
the MS/MS method. The fully reduced and alkylated Cα will be referred to as Cα-PhM2-





Figure 29: Peak 1: TCEP+NMM, peak 2, 3, 4,5 and 6: Contaminations, peak 7 Cα-PhM2 with the remaining disulfide-









Figure 31: Spectrum of peak with retention time 7.81, verifying that it is Cα-PhM2-NMM2. 
 
Cα was synthesized according to the method described in chapter 4.3. To check if it was 
oxidized to the native fold, it was analyzed and the bridges were allocated. This peptide was, 
as before mentioned in chapter 5.1, referred to as DRP1 until it was confirmed that it indeed 
was the native isomer of Cα.  
During a natural oxidation experiment performed by my fellow master student Børge 
Renmælmo, linear, unprotected DRP1 was left in milliQ water at room temperature for 
approximately one month. During this time, the peptide oxidized both into a non-native and 
the native isomer, with a ratio of approximately 1:1. The non-native isomer differed in 
UHPLC retention-time compared to the native isomer Cα. The chromatograms that show this 




Figure 32: Difference in retention time between DRP1 (2.58 minutes) and DRP1.2 (2.40 minutes) 
 This non-native isomer will from now on be referred to as DRP1.2. DRP 1.2 was analyzed 
and the isomer determined.  The only difference between the experiments conducted on Cα, 
DRP1, DRP1.2 and Cω, was the concentration of the peptide solution at hand. The Cα 
solution had a concentration of 37 µM, DRP1 was 81.5 µM, DRP1.2 was 80 µM and Cω was 
65.6 µM. The TCEP/maleimide concentrations were adjusted accordingly to give the 
appropriate molar ratios as decided in the methods described in chapter 4.5.1. 
The method worked well on both DRP1 and DRP1.2, which was expected, since DRP1 is the 
same peptide as Cα and DRP 1.2 has the same sequence but with different disulfide 
connectivity. Disappointingly, the bridging of Cω could not be solved by this method. It was 
not possible to break only one or even two of the three disulfide-bridges of Cω. It was either 
no reduction or full reduction of the peptide. Since pH needed to be 3, the only variables were 
the TCEP: Cω ratio and reaction time. The reaction time was first thought to be longer than 
was the case with Cα, but extending the reaction time only reduced unreduced Cω to fully 




 There are several aspects that may lead to this total reduction of Cω. As seen in Figure 2, Cω 
has a structure built from the secondary structure β-sheets and loops. β-sheets are less stable 
than α-helices, and a disruption of just one disulfide-bridge may be enough to unravel the 
whole fold. Less energy is then needed to break the remaining bridges than would be the case 
in an α-helical structure. When viewing Figure 2, it looks like the position of the disulfide-
bridges in the peptide is of a stacking manner, with the topmost bridge of Figure 2 connecting 
the two end-loops. This stacking may lead to less steric hindrance and therefore easier access 
for TCEP to the second disulfide-bridge in Cω than is the case for the second bridge of Cα. 
The properties of the AA in the peptide-sequence, such as hydrophobicity, bulkiness, pKa-
value and so on, might be more important factor to whether or not a partial reduction will take 
place than the number of disulfide-bridges.  
Hence, a reduction of just one disulfide-bridge in Cω would need a method that would 
stabilize the structure while only breaking the most accessible disulfide-bridge. A new method 
was developed, and since the aim of the thesis was to make a generic method, it was also 
tested out on Cα. 
 
5.3.2 Reduction and Alkylation on SPE-Column 
 
An attempt was made to develop a SPE method early on in the project. In the early attempt, 
2.22 nmole Conotoxin was reduced with a ratio of 50 molar equivalents of TCEP at pH 3 for 
6 minutes before it was applied to the conditioned SPE-column. The column was washed with 
3 mL milliQ water to rid the sample of excess TCEP. Finally, the peptide was eluted with 0.5 
mL 50 mM NMM in AcN. The eluate was examined on UHPLC-MS/MS, and no peptide-
signal was detected. These data are not shown. In retrospect, this was probably due to low 
concentration of peptide in the eluate. Seeing as this attempt failed and the method described 
in chapter 4.5.1 was a success for Cα, SPE as a tool to specifically break one disulfide-bridge 
in a DRP was left unresolved until it was clear that the method in chapter 4.5.1 could not be 
used on Cω.   
The SPE method was modified to the one described in chapter 4.5.2. At this stage, DRP1 had 
been successfully synthesized and the fold was verified by the method described in chapter 
4.5.1. For this reason, the amount of available Cα outclassed that of Cω, and Cα was used in 
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initially in the new SPE trial. Since the aim was to find a generic method, it had to be tested 
on both Conotoxins available.  
The modified SPE method proved a success. A truly specified cleavage of one disulfide-
bridge was obtained both with Cα and Cω. Chromatograms of both peptides gave signals 
corresponding to unreduced and fully reduced and alkylated variants of the peptides present. 
Figure 33 and Figure 34 are sections of the chromatograms from the sample derived from the 
SPE-induced reduction and alkylation of Cα and Cω, and show amongst other, the signals 
from Cα-PhM2 and Cω-PhM2 respectively. The strongest signal in both Figure 33 and Figure 
34  was the TCEP-PhM complex peak. The co-elution of TCEP and the peptide could not be 
avoided. It seemed TCEP and the peptide had a similar affinity to the SPE-column, and the 
PhM had to be introduced to the peptide-TCEP eluate as soon as possible to avoid post-
column reduction which would lead towards full reduction of the peptide if not stopped. There 
were contaminations visible in both chromatograms that had not been observed during the in-
vial experiments. A blank eluate, consisting of 80 % AcN with 0.1 % FA, was analyzed on the 
UHPLC-MS/MS instrument. After examining the chromatogram of the blank eluate, it was 
clear that the contaminations origins from the SPE-column. Extended washing of the column 
with solutions of various AcN-to-milliQ water ratios were unable to eliminate the 
contamination signals. Cα-PhM2, peak 2 in Figure 33, was the only signal corresponding to a 
peptide with one disulfide-bridge cleaved and alkylated while the other remained intact. The 
same was observed for Cω, only one signal where two disulfide-bridges were intact and one 
cleaved. If no disulfide scrambling occurred, and all three disulfide-bridges were cleaved to 
leave the peptide with one cleaved and two whole disulfide-bridges, there would be three 
signals with the same m/z in the chromatogram. The fact that there was not, shows that one 
disulfide-bridge was specifically cleaved. There were signals corresponding to Cω with two 
disulfide-bridges being cleaved and to the fully reduced Cω. More chromatograms and spectra 




Figure 33: A chromatogram of Cα from the SPE-method, 3.30-4.50 minutes displayed. Signal 1; TCEP-PhM, signal 2; 





Figure 34: Cω-PhM2 signal with retention time 2.30 dwarfed by the TCEP-PhM signal with retention time 2.50. The 
peak at 2.43 minutes is a contamination. 
 
After these preliminary tests the aim was to increase the volume of sample added to the SPE 
column, and adjust the amount of TCEP and PhM accordingly. The Cω-PhM2 would be 
separated from the rest of the components in the sample through the same manual purification 
method on the UHPLC-PDA as described in chapter 4.5.1. The prepared Cω-PhM2 would 
undergo a new reduction step on a SPE column, and eluted into an Eppendorf tube containing 
NMM. The Cω-PhM2-NMM2 would subsequently be treated equally to the Cω-PhM2 sample. 
The third and final reduction step would be carried out in the same manner, with the sample 
eluting in to a NEM solution, creating Cω-PhM2-NMM2-NEM2 ready for software mediated 
structure determination.  Due to unfortunate, long term damage to the UHPLC-MS/MS 
system, this remains unresolved at the end of the project period. Further development of the 





5.4 Structure Determination 
 
After a successful analysis, the MS/MS spectra acquired were compared to the theoretical 
CID- fragments calculated in the software program “MS-product” in the database “Protein 
prospector”. It was possible to identify which Cys-residues were coupled to which maleimide, 
and thereby establish the Cysteine-connectivity of the alkylated peptide. To simplify the 
different isomer sequences of Cα or any other two-bridged DRP, these may be illustrated by 
vvuu, vuvu or uvvu, as previously explained in chapter 4.7 and illustrated in Figure 16. The 
three sequences were defined in the “Protein Prospector” (PP) software. In Appendix 4, the 
theoretical values of fragment-ions formed upon CID-fragmentation of Cα-PhM2-NMM2 are 
shown. The fragment-ions actually observed are marked with red squares. The observed 
fragments are illustrated in Figure 35 with deviation from the theoretical value in ppm. 
 
Figure 35: The diagnostic ions observed upon CID-fragmentation of Cα-PhM2-NMM2. Theoretical values can be 




In Figure 36, the fragment with m/z 587.7556 is the base peak. This is as expected since 
Proline (Pro) induces fragmentation, making y7 the most prominent fragment. The y7 fragment 
of Cα was a diagnostic ion. If the isomer vvuu was the native fold with both C8 and C12 
alkylated with NMM, the m/z of the ion y7
2+
 would have been 556.7475 according to the PP. 
As the m/z of y7
2+
 was 587.7556, the sequence at hand must be uvuv, vuvu, vuuv or uvvu. The 
sequences uvuv and vuvu are the same isomer, only alkylated in the opposite order. The same 
is true for vuuv and uvvu, as illustrated in Figure 16. Fragmentation at residues four, five, six 
and seven in the sequence gives different length fragments all containing C8 and C12, and 
they all give information of the alkylation of these. However, not all of these fragments were 
observed. In addition to the before mentioned fragment y7
2+
 the fragments y5 and y6-NH3 were 
observed, and effectively ruled out the possibility of vvuu being the native sequence. Figure 
35 and Figure 36 shows their observed values  
 
Figure 36: CID-fragments of Cα-PhM2-NMM2, diagnostic ions a2, y5, y6 and y7 shown. 
 
Fragments y1-y4 and thus b8-b11 were diagnostic ions and would determine the alkylation of 
Cys8 and Cys12. Of these possible fragments only y2 and y4 were observed, and are shown in 
66 
 
Figure 37 and Figure 38. Fragment y4 had an m/z of 645.2921, which corresponds to the 
theoretical value of m/z 645.2926 if C12 was u (NMM). The y2-fragment had an m/z of 
388.1767, where PP’s theoretical value was 388.1761 if C12 was u (NMM). The difference 
between the actual observations and the theoretical fragments were 0.77 and 1.55 ppm 
respectively. An error of less than 25 ppm was considered acceptable. Hence, C12 was 
identified as u (NMM). Following this and the previous conclusion that vvuu could not be the 
isomer, C8 needed to be v (PhM). 
 




Figure 38: MS/MS spectrum of Cα-PhM2-NMM2 shows the presence of the diagnostic ion y4 with m/z 645.2921  
In Figure 36, fragment-ion a2 had an m/z of 306.0907, while the theoretical value for this ion 
whit Cys2 as v (PhM) was 306.0917. The difference between theoretical and empirical value 
was only 2.62 ppm and the ion therefore diagnostic for Cys2.  If Cys2 had been u (NMM), the 
theoretical value of fragment-ion a2 was 244.0755. Fragment-ion b2 also gave support to Cys2 
being v (NMM), with empirical value 334.0873 and 334.0856 as theoretical value for a 
fragment-ion containing v (NMM). Difference between actual and theoretical value was 5.09 
ppm. 
From these seven diagnostic ions, it was concluded that the sequence was vuvu (PhM-NMM-
PhM-NMM), connecting Cys-residues 2 and 8 in a disulfide-bridge and Cys-residues 3 and 12 
in a second. This corresponds to previous knowledge of the Cα fold. The Cα fold is illustrated 




Figure 39: Native fold of Cα ImI verified by UHPLC-MS/MS and PP. 
To verify that the synthesized DRP1 was correctly folded into the native fold of Cα, the 
MS/MS spectra of DRP1-PhM2-NMM2 was simply compared to the spectra of the standard 
Cα-PhM2-NMM2. The diagnostic ions found for Cα-PhM2-NMM2 were also found for DRP1-
PhM2-NMM2. The fragments of Cα-PhM2-NMM2 and DRP1-PhM2-NMM2 are compared in 
Figure 40. By the reasoning above, DRP1 was thus proven to have the native fold, and could 
be renamed Cα. 
 
Figure 40: Comparison of the CID-fragment-ions of Cα-PhM2-NMM2 and DRP1-PhM2-NMM2. The most intense 
diagnostic ions are marked with red circles. The two spectra are sufficiently similar to conclude that the two peptides 




To further strengthen the conclusion that DRP 1 was the native isomer, MS/MS analysis of 
both fully reduced Cα and Cα alkylated with NMM in all four positions was performed. The 
diagnostic ions of Cα-NMM4 had different m/z compared to Cα-PhM2-NMM2, since two PhM 
with monoisotopic mass 173.055 amu was replaced with NMM with monoisotopic mass 
111.0399 amu. The spectra may be viewed in Appendix 4. The theoretical values of the 
fragment-ions that can be formed upon CID-fragmentation of Cα-NMM4 from PP can be 
viewed in Appendix 4. The observed values and the deviation from the theoretical values are 
illustrated in Figure 41.  
 
Figure 41: The diagnostic ions observed upon CID-fragmentation of Cα-NMM4. 
 
The MS/MS spectrum of DRP 1.2-PhM2-NMM2, the non-native fold of Cα formed during 
oxidative folding of the linear synthesized peptide was compared to the theoretical values of 
the fragment ions in PP. Diagnostic ions y2, y4, y5, y6 and y7 all had the same values as in Cα-
PhM2-NMM2 and DRP1-PhM2-NMM2, indicating that there was no difference in the 
alkylation of C8 and C12. This meant that C8 = v (PhM) and C12 = u (NMM) also in        
DRP 1.2, based on the knowledge from diagnostic ions y2, y5, y6-NH3 and y7
2+
. Fragment ions 
a2 and b2, had m/z 244.0755 and 272.0705 respectively, corresponding to a fragment where C2 
was u (NMM) and not v (PhM) as was the case of Cα.  
Figure 42 illustrates the observed fragment-ions and the deviation from the theoretical value 
from PP. The theoretical values from PP may be viewed in Appendix 4. The spectra with the 
diagnostic ions marked may be viewed in Appendix 4. Figure 42 compares the spectra of 
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DRP1 and DRP1.2. The figure shows the difference in m/z for diagnostic ion a2 and that m/z 
for the diagnostic ions y7
2+
 and y5 are the same in the two peptides.  
 
Figure 42: The diagnostic ions observed upon CID-fragmentation of DRP1.2-PhM2-NMM2. 
 
 
Figure 43: DRP1.2-PhM-NMM and DRP1-PhM-NMM on top of each other. Fragment ion a2 differs, y7
2+ and y5 are 




The seven observed diagnostic ions showed in Figure 42 confirmed the theory that DRP 1.2 
was the non-native isomer uvvu shown in Figure 44. 
 




6. Future Perspectives 
 
The aim of the thesis was to find a generic method of allocating Cysteine-connectivity for 
DRPs, and ideally a method that in the course of one work flow could identify samples of 
minute amount. This was not accomplished through these experiments, and needs further 
attention.  
Since the unfortunate instrument break-down hindered the full exploration of the SPE-
method, this needs to be further investigated in the future. Should the method prove to work 
as anticipated, it needs to be tried on several peptides differing in qualities such as sequence, 
hydrophobicity, number of Cys-residues and others.   
In future experiments the use of digestive enzymes with well-known and –studied active sites 
which will cut the peptide-chain between foreseen AAs could be used to obtain anticipated 
fragments. These fragments could be analyzed by other software or databases to determine the 
final structure and Cysteine-connectivity. 
Another path worth further investigation is the use of scavenger columns. The solid phase of 
these SPE-columns contains thiol-groups that will quench any remaining maleimide from the 
solution, readying it for further reduction without the time consuming and imprecise fraction- 






A successful synthesis of Cα was a performed with neither Cysteine racemization nor 
aspartamide formation detected. The purification of the crude resulted in a 95 % purity of the 
linear, Acm-protected peptide. The chemical oxidation ensured correct cysteine-connectivity 
in the peptide. 
TCEP solutions were not found to be as effective as proclaimed in previous papers. At pH 3, 
both the reaction time and ratio needed were higher than at the recommended pH 5.5. 
The self-synthesized Cα, the commercially bought Cα, and the naturally oxidized peptide 
DRP1.2 were all analyzed by the method to determine isomer and Cysteine-connectivity in 
DRPs with two disulfide-bridges that was found. Both peptide solutions and TCEP-solutions 
had to be made with ammonium formate buffer with pH 3 to prevent disulfide scrambling. 
The maleimides had to be dissolved in AcN to prevent unwanted reactions between 
maleimide and water and/or MeOH. Because of the different reaction stages present in a 
peptide sample with one bridge reduced and alkylated, the Cα-PhM2 fraction needed to be 
isolated. 
 A generic MS/MS method gave sufficiently adequate results to compare observed fragment-
ions with theoretical ions calculated by the chosen software, Protein Prospector. The 
disulfide-connectivity of the self-synthesized Cα, the commercially bought Cα, and the 
naturally oxidized peptide DRP1.2 were all verified. This was accomplished by comparing the 
ions obtained upon CID-fragmentation of the peptides with each bridge alkylated with a 
different maleimide with the theoretical values of these ions  
The generic SPE-method for reducing and alkylating disulfide-bridges of all DRPs regardless 
of number of bridges shows potential. There is still much work ahead to develop the SPE-
method, and other methods such as a method involving scavenger columns or digestive 
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Appendix table 1: 100 µM First coupling with resin swelling and double coupling; Volume in µL, time in minutes: 
seconds,  concentrations in M. The table is modified from the software of the Prelude peptide synthesizer. 
Operation Volume Mix time  Repetitions Reagents/ action 
DMF top wash 5000 1:00 3 Resin swell 
Deprotection 2500 5:00 1 Piperidine 
Deprotection 2500 10:00 1 Piperidine 
DMF top wash 2500 0:30 5 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution 
Activator 1300 - 1 0.4 M HCTU 
Strong Base 1000 30:00 1 1.0 M DIPEA 
DMF top wash 2500 0:30 1 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution 
Activator 1300 - 1 0.4 M HCTU 
Strong base 1000 30:00 1 1.0 M DIPEA 











Appendix table 2: Standard 100 µM double coupling and capping; Volume in µL, time in minutes: seconds, 
concentrations in M. The table is modified from the software of the Prelude peptide synthesizer. 
Operation Volume Mix time Repititions Reagents 
Deprotection 2500 5:00 1 Piperidine 
Deprotection 2500 10:00 1 Piperidine 
DMF top wash 2500 0:30 5 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution 
Activator  1300 - 1 0.4 M HCTU 
Strong Base 1000 30:00 1 DIPEA 
DMF top wash 2500 0:30 1 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution 
Activator  1300 - 1 0.4 M HCTU 
Strong Base 1000 30:00 1 DIPEA 
DMF top wash 2500 0:30 5 DMF 
Capping 2500 15:00 1 20 % acetic anhydride 
20 % pyridine in DMF 



















Appendix table 3: 100 µM Cysteine double coupling and capping program. Volume in µL, time in minutes: seconds, 
concentrations in M. The table is modified from the software of the Prelude peptide synthesizer. 
Operation Volume Mix time Repititions Reagents 
Deprotection 2500 5:00 1 Piperidine 
Deprotection 2500 10:00 1 Piperidine 
DMF top wash 2500 0:30 5 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution 
Activator 1300 - 1 0.4 M HCTU 
Weak base 1000 30:00 1 1.0 M TMP 
DMF Top Wash 2500 0:30 1 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution 
Activator 1300 - 1 0.4 M HCTU 
Weak base 1000 30:00 1 1.0 M TMP 
DMF top wash 2500 0:30 5 DMF 
Capping 2500 15:00 1 20 % acetic anhydride 
20 % pyridine in DMF 



















Appendix table 4: 100 µM final double coupling program; Volume in µL, time in minutes: seconds, concentrations in 
M. The table is modified from the software of the Prelude peptide synthesizer.  
Operation Volume Mix time Repetitions Reagents 
Deprotection 2500 5 1 Piperidine 
Deprotection 2500 10 1 Piperidine 
DMF top wash 2500 0:30 5 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution 
Activator 1300 - 1 0.4 M HCTU 
Strong Base 1000 30 1 DIPEA 
DMF top wash 2500 0:30 1 DMF 
AA Building Block 2500 - 1 0.2 M Fmoc solution  
Activator 1300 - 1 0.4 M HCTU 
Strong Base 1000 30: 1 DIPEA 
DMF top wash 2500 0:30 3 DMF 
Deprotection 2500 5 1 Piperidine 
Deprotection 2500 10 1 Piperidine 







Activity Studies of TCEP 
 
Experiment 1; TCEP activity and pH 
 
Appendix table 5: Absorbance of DNTB and TCEP solution measured at pH 2, each parallel was measured                                          
three times at three different times; t is measured in minutes.                                                                                                    
An average value for each parallel was calculated. 
pH 2 t= 0 t= 15 t= 30 
Parallel 1, measurement 1 0.10518 0.10726 0.11614 
Parallel 1, measurement 2 0.10577 0.10759 0.11622 
Parallel 1, measurement 3 0.10448 0.10732 0.1164 
Average 1 0.10514 0.10739 0.116253 
Parallel 2, measurement 1  0.10577 0.11417 0.11637 
Parallel 2, measurement 2 0.10503 0.11424 0.11603 
Parallel 2, measurement 3 0.10523 0.11417 0.11625 
Average 2 0.10534 0.11419 0.11622 
Parallel 3, measurement 1 0.10325 0.11285 0.11699 
Parallel 3, measurement 2 0.10445 0.11229 0.11698 
Parallel 3, measurement 3 0.10474 0.11298 0.11706 
Average 3 0.10415 0.11271 0.11701 
 
 
Appendix table 6: Absorbance of DNTB and TCEP solution measured at pH 3, each parallel was measured                                          
three times at three different times; t is measured in minutes.                                                                                                    
An average value for each parallel was calculated. 
pH 3 t= 0 t= 15 t= 30 
Parallel 1, measurement 1 0,11463 0,12007 0,12419 
Parallel 1, measurement 2 0,1149 0,11975 0,12418 
Parallel 1, measurement 3 0,11523 0,11984 0,12429 
Average 1 0,11492 0,11989 0,12422 
Parallel 2, measurement 1 0,1124 0,12089 0,1243 
Parallel 2, measurement 2 0,11231 0,12111 0,12466 
Parallel 2, measurement 3 0,11257 0,12116 0,12487 
Average 2 0,11243 0,12105 0,12461 
Parallel 3, measurement 1 0,11711 0,11648 0,12082 
Parallel 3, measurement 2 0,11706 0,11728 0,121 
Parallel 3, measurement 3 0,11731 0,11714 0,12148 




Appendix table 7: Absorbance of DNTB and TCEP solution measured at pH 4, each parallel was measured                                          
three times at three different times; t is measured in minutes.                                                                                                    
An average value for each parallel was calculated. 
pH 4 t= 0 t= 15 t= 30 
Parallel 1, measurement 1 0.19328 0.2477 0.25418 
Parallel 1, measurement 1 0.208 0.24726 0.25412 
Parallel 1, measurement 1 0.21877 0.24767 0.25415 
Average 1 0.20668 0.24754 0.25415 
Parallel 2, measurement 1 0.27793 0.32754 0.33935 
Parallel 2, measurement 2 0.28772 0.3262 0.3393 
Parallel 2, measurement 3 0.29611 0.32828 0.33945 
Average 2 0.28725 0.32734 0.33937 
Parallel 3, measurement 1 0.20267 0.25534 0.27149 
Parallel 3, measurement 2 0.21932 0.25534 0.27177 
Parallel 3, measurement 3 0.22891 0.25655 0.27216 
Average 3 0.21697 0.25574 0.27181 
 
 
Appendix table 8: Absorbance of DNTB and TCEP solution measured at pH 2, each parallel was measured                                          
three times at three different times; t is measured in minutes.                                                                                                    
An average value for each parallel was calculated. 
pH 5 t= 0 t= 15 t= 30 
Parallel 1, measurement 1 0.27682 0.53065 0.54416 
Parallel 1, measurement 2 0.31957 0.53033 0.54449 
Parallel 1, measurement 3 0.36444 0.52986 0.54517 
Average 1 0.32028 0.53028 0.54461 
Parallel 2, measurement 1 0.32117 0.54466 0.56335 
Parallel 2, measurement 2 0.37896 0.54486 0.56258 
Parallel 2, measurement 3 0.40832 0.54485 0.5626 
Average 2 0.36948 0.54479 0.56284 
Parallel 3, measurement 1 0.29957 0.58873 0.59308 
Parallel 3, measurement 2 0.37413 0.58977 0.59439 
Parallel 3, measurement 3 0.41991 0.58912 0.59537 





Appendix table 9: Absorbance measured at pH 6, each parallel was measured three times at three different times;                                            
t is measured in minutes. An average value for each parallel was calculated. 
pH 6 t= 0 t= 15 t= 30 
Parallel 1, measurement 1 0.34731 0.68768 0.70256 
Parallel 1, measurement 2 0.40101 0.68769 0.70099 
Parallel 1, measurement 3 0.44115 0.68707 0.70207 
Average 1 0.39649 0.68748 0.70187 
Parallel 2, measurement 1 0.35696 0.74112 0.75453 
Parallel 2, measurement 2 0.42474 0.74053 0.75439 
Parallel 2, measurement 3 0.46488 0.74181 0.75289 
Average 2 0.41553 0.74115 0.75394 
Parallel 3, measurement 1 0.33268 0.70628 0.72642 
Parallel 3, measurement 2 0.40538 0.70637 0.72674 
Parallel 3, measurement 3 0.4447 0.7084 0.72686 






Experiment 2; TCEP activity at different ratios 
 
Appendix table 10: Absorbance of DNTB and TCEP solution measured at ratio 1:2,                                                                                                
each parallel was measured three times at two different times; t                                                                                           
is measured in minutes. An average value for each parallel was calculated. 
Ratio 1:2 t=0 t=15 
Parallel 1, measurement 1 0.28075 0.29295 
Parallel 1, measurement 2 0.24916 0.29295 
Parallel 1, measurement 3 0.27129 0.29342 
Average 1 0.26707 0.29311 
Parallel 2, measurement 1 0.25882 0.30362 
Parallel 2, measurement 2 0.28827 0.30441 
Parallel 2, measurement 3 0.27907 0.30457 
Average 2 0.27539 0.3042 
Parallel 3, measurement 1 0.24529 0.2924 
Parallel 3, measurement 2 0.26847 0.29254 
Parallel 3, measurement 3 0.27861 0.29217 
Average 3 0.26412 0.29237 
 
Appendix table 11: Absorbance of DNTB and TCEP solution measured at ratio 1:5,                                                                                                
each parallel was measured three times at two different times; t                                                                                           
is measured in minutes. An average value for each parallel was calculated. 
Ratio 1:5 t= 0 t= 15 
Parallel 1, measurement 1 0.30493 0.3164 
Parallel 1, measurement 2 0.31218 0.31624 
Parallel 1, measurement 3 0.31187 0.31585 
Average 1 0.30966 0.31616 
Parallel 2, measurement 1 0.32178 0.32579 
Parallel 2, measurement 2 0.32106 0.3267 
Parallel 2, measurement 3 0.31694 0.32665 
Average 2 0.31993 0.32638 
Parallel 3, measurement 1 0.30484 0.31597 
Parallel 3, measurement 2 0.30989 0.3155 
Parallel 3, measurement 3 0.30972 0.31527 





Appendix table 12: Absorbance of DNTB and TCEP solution measured at ratio 1:10,                                                                                                
each parallel was measured three times at two different times; t                                                                                           
is measured in minutes. An average value for each parallel was calculated. 
Ratio 1:10 t= 0 t= 15 
Parallel 1, measurement 1 0.33956 0.34259 
Parallel 1, measurement 2 0.33951 0.34358 
Parallel 1, measurement 3 0.33844 0.34398 
Average 1 0.33917 0.34338 
Parallel 2, measurement 1 0.34952 0.35012 
Parallel 2, measurement 2 0.34951 0.3508 
Parallel 2, measurement 3 0.34896 0.35039 
Average 2 0.34933 0.35044 
Parallel 3, measurement 1 0.34152 0.35167 
Parallel 3, measurement 2 0.34267 0.35216 
Parallel 3, measurement 3 0.342 0.35178 





MS/MS Method Tables 
 
Appendix table 13: MassLynx settings, charge state +1, the m/z value trigger a change in collision energy   
Charge state m/z Collision energy (eV) 
 300 22 
+1 785 32 
 955 55 
 
 
Appendix table 14: MassLynx settings, charge state +2, the m/z value trigger a change in collision energy   
Charge state m/z Collision energy (eV) 
 400 25 
+2 785 32 
 820 37 
 1200 57 
 1500 72 
 2000 90 
 
 
Appendix table 15: MassLynx settings, charge state +3, the m/z value trigger a change in collision energy   
Charge state m/z Collision energy (eV) 
 435 21 
+3 547 28 
 605 31 
 1000 42 
 1500 55 
 1800 65 
 
 
Appendix table 16: MassLynx settings, charge state +4, the m/z value trigger a change in collision energy    
Charge state m/z Collision energy (eV) 
 435 18 
+4 547 25 
 605 28 





UHPLC Chromatograms and MS Spectra  
 
 
Appendix figure 1: Peak 1: Injection peak, Peak 2: split peak TCEP, peak 3: TCEP, peak 4: One disulfide-bridge 




Appendix figure 2: Cα alkylated with NMM. Peak 1: unreacted Cα, peak 2: Cα-NMM2, peak 3: contamination and 





Appendix figure 3: Two MS/MS chromatograms of DRP1 and one from DRP1.2 at the bottom. Retention time and 





Appendix figure 4: Chromatogram of attempted reduction of one disulfide-bridge in Cω. Peak 1 and 2 and the tailing 
marked with the red ellipse all come from unreduced Cω. Different folding of the same isomer of the peptide can give 





Appendix figure 5: Analysis of blank eluate from the SPE-column. Signals detected are contaminations and not 





Appendix figure 6: Chromatogram from the SPE-method, Cα-PhM2 marked with a red circle. Compare with the 










Appendix figure 8: Chromatogram from the SPE-method, Cω-PhM2 marked with a red circle and number 3. 
Compare with the blank eluate to see which peaks are the contaminants. Signal 1 and 2 are different folds of the 
native isomer of Cω, m/z = 760.0571 and 760.0554 respectively. z in this case is 5. Signal 4 is the TCEP-PhM product. 















Appendix figure 10: Theoretical values of b and y ions formed upon CID-fragmentation of Cα-PhM2-NMM2, observed 





Appendix figure 11: Theoretical values of additional ions formed upon CID-fragmentation of Cα-PhM2-NMM2, 





Appendix figure 12: Theoretical values of b and y ions formed upon CID-fragmentation of DRP1.2-PhM2-NMM2, 






Appendix figure 13: Theoretical values of additional ions formed upon CID-fragmentation of DRP1.2-PhM2-NMM2, 






Appendix figure 14: Theoretical values of b and y ions formed upon CID-fragmentation of Cα-NMM4, observed ions 






Appendix figure 15: Theoretical values of additional ions formed upon CID-fragmentation of Cα-NMM4, observed 










Appendix figure 17: MS/MS of fully reduced Cα with all four sulfhydryl-groups alkylated with NMM. Fragment-ions 





Appendix figure 18: MS/MS of DRP 1.2, diagnostic ions a2, y7









Appendix figure 20: MS/MS of DRP 1.2, diagnostic ions y4 and y5 
 
 
